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ABSTRACT 
 
COMFORT, KRISTEN KRUPA.  Signaling Pathways Activated by Interleukin-2 and 
Interluekin-4 Receptors Mediate T Lymphocyte Clonal Expansion. (Under the direction of 
Dr. Jason M. Haugh). 
 
 
Cells sense and respond to chemical and physical stimuli through signal transduction 
pathways, which mediate cell proliferation, differentiation, migration, and survival.  The 
cytokines interleukin-2 (IL-2) and interleukin-4 (IL-4) are key regulators of the adaptive 
immune system, particularly influencing the clonal expansion and differentiation of T cells.  
At least in culture, both synergistic and antagonistic effects of IL-2 and IL-4 co-stimulation 
have been reported; the antagonism, when observed, is thought to arise from the utilization of 
a common subunit shared by IL-2 and IL-4 receptors.  We have sought to characterize IL-2 
and IL-4 signaling at the level of intracellular pathways activated by these receptors.  IL-2 
receptors are known to activate the Ras/extracellular signal-regulated kinase (Erk) and 
phosphoinositide (PI) 3-kinase/Akt pathways as well as the STAT5 transcription factor.  IL-4 
is unique among cytokines in that it does not activate Ras/Erk; it does activate PI 3-
kinase/Akt as well as a distinct STAT, STAT6. 
 
The HT-2 mouse T cell line responds to both IL-2 and IL-4.  We found that IL-4 initially 
antagonizes, and later synergizes with, IL-2-stimulated HT-2 cell proliferation in a dose-
dependent manner.  Additionally, transient signaling through the PI3K/Akt and Ras/Erk 
pathways are required for optimal T cell proliferation.  IL-4 stimulates cell adhesion in static 
cultures, again in a dose-dependent fashion, and it partially inhibits IL-2-stimulated 
activation of Akt, Erk and STAT5, consistent with a competition effect.  IL-2/IL-4 co-
stimulation provokes transient activation of Akt, Erk and STAT5 coupled with prolonged 
activation of STAT6.  This signaling profile and the cell adhesion response suggest potential 
mechanisms by which IL-4 influences the proliferation of helper T cells.   
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CHAPTER 1 
 
INTRODUCTION AND OVERVIEW PART 1: 
IL-2 AND IL-4 INDUCED PROLIFERATION AND DIFFERENTIATION 
OF T CELLS AND THEIR FUNCTIONS IN THE IMMUNE RESPONSE  
 
 
1.1  MOTIVATION AND RESEARCH SIGNIFICANCE 
 
The ability of living cells to recognize and respond to chemical and physical stimuli in their 
surrounding environment is fundamental for life.  The biochemical mechanisms responsible 
for processing this information inside the cell are collectively referred to as signal 
transduction.  These mechanisms involve enzyme-catalyzed reactions and formation of 
noncovalent protein-protein and protein-lipid complexes (24).  In the most simplistic 
scenario, an external perturbation binding to a surface receptor would initiate one signal 
cascade leading directly to a cellular outcome (Figure 1.1).  However, most receptors are 
pleiotropic, meaning that they simultaneously trigger multiple signaling pathways and 
outcomes.  Further, individual signaling pathways have the ability to modulate the activities 
of other pathways; through so-called crosstalk interactions.  When also considering pathway 
cooperation and the presence of multiple concurrent stimuli, it becomes apparent that the 
dynamics of signal transduction are extremely complex (20, 31). 
 
The cytokines interleukin-2 (IL-2) and interleukin-4 (IL-4) are key regulators of the immune 
system, particularly influencing the function of T lymphocytes.  IL-2 induces a strong 
proliferative effect in T cells, whereas IL-4 causes differentiation (22, 26).  When T cells are 
exposed to these stimuli in concert, a synergistic effect transpires that generates rapid growth 
and differentiation, known as clonal expansion (48). 
 
There is a strong desire to fully understand, at the molecular level, how this observed synergy 
arises, particularly the involvement of specific signaling proteins.  Through experimental 
quantification of the signal transduction network, it may be possible to fundamentally  
analyze and reproduce cytokine-induced clonal expansion of T cells.  This knowledge could 
be a powerful tool in bolstering the immune response in the fight against cancer and other 
diseases.   
 
C
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Figure 1.1  Activation pathways of signal transduction networks  Linear signal 
transduction networks are initiated by a perturbation, in this case a cytokine (C), binding to 
its specific receptor (R) and triggering the activation of a signaling pathway (S), which leads 
to a cellular outcome (O).  A pleiotropic cytokine will give rise to multiple signaling 
pathways that may each control a unique outcome.  As these multiple pathways have the 
potential to laterally influence each other, known as signal crosstalk, it adds another layer of 
complexity to the transduction network.  Often more than one stimulus can affect a cell, with 
each growth factor activating several pathways that could potentially initiate crosstalk: 
creating a very convoluted system. 
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1.2 BACKGROUND 
 
1.2.1 T cell function and its role in the immune system 
 
The innate immune response provides the body’s first line of defense against common 
microorganisms and is essential in combating bacterial infections.  The cells of the innate 
system non-specifically target foreign pathogen for removal or destruction of infected cells.  
However, the innate immunity is not always sufficient to win this battle, and in some cases it 
fails to even recognize its pathogenic opponents (8).  Over time, the immune system has 
evolved to incorporate a more versatile means of guarding itself from these pathogens - the 
adaptive immune response.  Adaptive immunity provides not only increased protection 
against a wide variety of foreign pathogens, but also a means of summoning this protection 
quickly in the face of a subsequent attack (62).  The innate immune cells serve to activate and 
direct the cells of the adaptive immune system, showing how these two defensive fronts work 
together to fight off foreign invaders and infection. 
 
The T lymphocyte, or T cell, is a key member of the adaptive immune system.  T cells arise 
from the bone marrow, where they begin as hematopoietic stem cells (12).  These stem cells 
have the ability to differentiate into one of many different immune cells including T cells, B 
cells, dendritic cells and several other leukocytes (50).  These precursor T cells then leave the 
bone marrow and migrate to the cortex of the thymus, where they undergo a maturation 
process that involves gene rearrangement (2).   
 
After successfully completing gene rearrangement, the cells begin the process of positive 
selection.  An antigen presenting cell (APC) binds to and activates a T cell through its major 
histocompatibility complex (MHC), of which there are two classes: MHC class I and MHC 
class II.  Immature T cells that recognize MHC class I develop into cytotoxic T cells (TC 
cells), whereas cells that bind MHC class II mature into helper T cells (TH cells) following 
further selection.  Precursor cells that fail to recognize either form of MHC do not receive a 
developmental signal from the APC and die of neglect (27, 57, 59). 
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Immature T cells then migrate into the medulla of the thymus and undergo the process of 
negative selection.  The cells are presented “self” peptides by APCs and are tested to see if 
they respond.  During this phase, any precursor cell that recognizes “self” is given a death 
signal that induces apoptosis and is thus removed from the repertoire (50, 57).  Self-reactive 
T cells that mistakenly survive negative selection can lead to the development of several 
autoimmune diseases, causing the immune system to attack one’s own body (23).  The above 
process, in its entirety, is referred to as clonal selection and results in the production of a 
mature yet naïve T cell population that each recognizes a unique peptide sequence. 
 
After a foreign pathogen enters the body, it is phagocytosed, broken down into small peptide 
sequences and displayed by an APC.  Upon leaving the thymus each of these mature T cells, 
having now become a naïve TC or TH cell, circulates through the peripheral lymphoid organs 
and searches for the APC that is displaying the sole peptide sequence that it recognizes (46).  
Once a T cell finds its correct antigen, two independent signals must occur for it to transform 
from a naïve cell to an activated, armed T cell.  First, the peptide/MHC complex must 
successfully bind to the T cell receptor and transmit a signal that the correct antigen has been 
encountered.  A co-stimulatory signal must also be delivered to the T cell from the same 
APC for full activation and the induction of gene alteration (65).  These co-stimulatory 
signals usually involve the interaction between molecules on the surfaces of the T cell and  
APC, such as CD28 and B7, respectively  (17, 56).    
 
After a T cell becomes activated, it initiates the secretion of IL-2, which binds to the 
specialized IL-2 receptors on the T cell surface - driving cellular proliferation and 
differentiation (26).  After rapid proliferation, cytotoxic T cells are ready to perform their 
effector function of seeking out and delivering lethal signals to infected cells in the body, 
whereas helper T cells must undergo further differentiation.  
 
Naïve TH cells can differentiate into either TH1 or TH2 cells, which differ in the cytokines they 
produce as well as their functions (Figure 1.2).  TH1 cells activate macrophages, enabling 
them to phagocytose and destroy pathogenic microorganisms more efficiently, whereas TH2 
cells drive B lymphocytes to differentiate and initiate the production of antibodies (42).  The 
cytokines secreted by a helper T cell subset establishes a positive feedback loop that 
promotes the differentiation of other TH cells to that particular subset while simultaneously 
blocking the differentiation into the second subset (1, 42).  For example, interferon-γ (IFN-γ) 
is produced in significant quantities from TH1 cells.  IFN-γ can then favor the differentiation 
of TH to TH1 cells while acting as an antagonist for TH2 development (9).  Similarly, the 
secretion of IL-4 from TH2 cells promotes the differentiation of additional TH2 cells (22, 54).  
In the case of the TH2 subset, IL-4 can synergize with IL-2 with respect to growth, which 
greatly enhances T cell expansion and effectiveness (58). 
 
 
Figure 1.2  Cytokine induced TH cell differentiation  After a mature, yet naïve TH cell 
encounters its specific antigen it secretes IL-2, inducing rapid proliferation.  Once primed, a 
TH cell can differentiate into either a TH1 or a TH2 subset, responsible for stimulating the 
development of either macrophages or B cells, respectively.  This differentiation is cytokine 
driven, with IFN-γ provoking TH1 development and IL-4 stimulating TH2 cells.  These 
cytokines not only trigger the differentiation of one TH subset, but also act as an antagonist 
toward the other; for example IL-4 simultaneously induces TH2 progression while inhibiting 
TH1 differentiation.  
 
After the adaptive immune system is activated, the foreign pathogen can be cleared by 
multiple routes.  TC cells, along with other specialized immune cells, recognize and kill tissue 
cells that have become infected by the pathogen.  As a side note, the possibility of priming 
and activating TC cells with IL-2 has been investigated as a mechanism for cancer therapy, 
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however this treatment has been abandoned due to the fact that it is nearly impossible for the 
TC cells to recognize and preferentially attack the tumor (25, 51).  
 
At the same time, the macrophages activated by TH1 cells and the massive amounts of 
antibodies secreted by the B lymphocytes following activation by TH2 cells target and 
eliminate all the remaining pathogen.  It becomes nearly impossible for a microorganism to 
survive such an attack, and following its removal, the immune system quickly returns the 
body to a state of homeostasis.  After they have completed their function, most effector cells 
will die; however, a few T and B cells become memory cells, which continue to live and can 
readily proliferate upon reintroduction of the same pathogen (6). 
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1.2.2  IL-2, IL-4 and their receptors
 
IL-2 function 
 
Interleukin-2 is a 15.5 kDa pleiotropic cytokine, secreted by activated T cells, that plays an 
immensely important role in activating the adaptive immune system; due to its capability of 
serving as both an autocrine and a paracrine factor.  In simple terms, a cytokine is a molecule 
secreted by one cell that acts upon another (44).  Because IL-2 is critical for the clonal 
expansion of T cells, it is also commonly referred to as T cell growth factor (29).  Clonal 
expansion consists of two concurrent processes: accelerated progress through the cell cycle 
and the induction of increased cell survival.  In addition to its role in T cell growth, IL-2 
mediates multiple biological processes, including growth and differentiation of B cells, 
creation of lymphokine-activated killer cells and expansion of natural killer cells (32).  
Recently, the role of IL-2 as a negative regulator of cell growth has also arisen.  It is believed 
that after antigen eradication, IL-2 triggers activation-induced cell death (AICD), reversing 
its effect on T cell expansion and returning the body to homeostasis (13). 
 
IL-2 receptor structure 
 
After its secretion, IL-2 binds to a specific, multi-subunit receptor complex.  The cell surface 
IL-2 receptor (IL-2R) is composed of three distinct subunits; the IL-2Rα, IL-2Rβ and γc (γ 
common) chains (Figure 1.3 a).  The IL-2Rα subunit is a 55 kDa membrane glycoprotein 
capable of binding IL-2.  Although the α chain plays a critical role in ligand capture and 
stabilization of the complex, it does not directly contribute to intracellular signaling, due to 
an extremely short cytoplasmic tail (29).  In contrast, the IL-2Rβ (p75) and γc (p64) chains 
together are both necessary and sufficient to initiate the signaling cascades (38).   
 
Figure 1.3  The IL-2 and IL-4 receptor complexes  a)  The IL-2R is composed of three 
subunits: the IL-2Rα, the IL-2Rβ and γc.  Only the IL-2Rβ and γc chains participate in signal 
transduction, with each containing a Box 1 and Box 2 motif to which Jak binds.  The IL-2Rβ 
can be functionally broken down into three domains: a serine-rich (S) domain, an acidic-rich 
(A) domain and a proline-rich (H) domain.  Within the A and H domains lie six conserved 
tyrosine residues that serve as docking sites for signaling proteins following receptor 
activation.  b)  The IL-4R consists of the IL-4Rα and γc subunits, both of which contain the 
membrane proximal Box 1 and Box 2 regions necessary for receptor activation.  In addition 
to the Jak binding region, the IL-4Rα contains three additional domains: the I4R region that 
binds with the IRS 1/2, the gene activating and the inhibitory ITIM domains.  Five conserved 
tyrosine residues necessary for signal transduction exist within the IL-4Rα.   
 
The three subunits can be assembled to give various forms of the IL-2 receptor, which 
predictably display vastly different ligand affinities and signaling capabilities.  Three distinct 
IL-2R complexes have been identified and are summarized in Table 1.1: a low affinity, an 
intermediate affinity and a high affinity.  Neither IL-2Rβ nor γc alone has significant affinity 
for IL-2 or is capable of inducing signal transduction (32).  On the other hand, IL-2Rα by 
itself has a low but significant binding affinity for IL-2 (Kd = 10 nM).  When IL-2Rβ and γc 
come together, they form an intermediate affinity receptor (Kd = 1 nM), which commences a 
low level of signaling (29).  Finally, the trimeric IL-2Rα/IL-2Rβ/γc complex represents the 
“classic” high affinity IL-2 receptor (Kd = 10 pM) which signals efficiently after stimulation 
with biological concentrations of ligand (15, 29, 32). 
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Table 1.1  IL-2 receptor compositions and ligand affinities 
 Low Intermediate High 
Subunits α β/γc α/β/γc
Approximate Kd 10 nM 1 nM 10 pM 
Signaling? No Yes – Incomplete Yes – Complete 
 
A common theme in cytokine signaling is that the cytokines themselves are both pleiotropic 
and redundant.  A possible explanation for this becomes clear when one considers the 
reoccurrence and sharing of receptor subunits among cytokines.  For instance, the γc subunit 
utilized in the IL-2 system is also a component of the IL-4, IL-7, IL-9, IL-15 and IL-21 
receptor complexes (44).  Loss of γc can have wide-ranging consequences on the immune 
system, correlating with a cell’s inability to respond to any of the aforementioned cytokines.  
This is demonstrated by the discovery that a deleterious mutation in γc causes severe 
combined immunodeficiency (SCID) in humans (41, 52). 
 
 It was quickly discovered that the majority of signaling events that occur after cytokine 
stimulation are mediated by the IL-2Rβ chain; hence, a functional analysis of this subunit 
was undertaken.  Analysis of the amino acid sequence of the IL-2Rβ cytoplasmic region 
identified 3 distinct regions (19).  The region closest to the plasma membrane was called the 
serine-rich region (S region) and consists of amino acids 267-322.  Directly following the S 
region of the receptor was found to be an acidic-rich domain (A region), comprised of amino 
acids 313-382.  This is followed by the carboxyl terminal proline-rich region (H region), 
which includes amino acids 378-525 (18, 19).  IL-2Rβ mutants lacking each of these 
domains were created and served as the initial research tool in the determination of the 
functionality of each domain.  For example, it became clear that S domain was required for 
cell proliferation, and the A section was necessary for activation of tyrosine kinases such as 
Lck and Fyn (11, 30, 33).  Further research into the sequence of IL-2Rβ revealed two highly 
conserved membrane-proximal sequences dubbed Box1 and Box 2, spanned by a variable 
domain termed the V Box (43).  Later, it became clear that characterizing the IL-2Rβ in 
terms of three domains was not specific enough, and a more detailed receptor analysis was 
undertaken. 
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IL-2 signaling initiation 
 
The binding of IL-2 to its receptor complex induces a heterodimerization of the IL-2Rβ and 
γc cytoplasmic domains.  Studies have shown that this heterodimerization is both required 
and sufficient for the initiation of IL-2 dependent intracellular signal transduction in T cells 
(38, 40).  Many growth factor receptors have intrinsic tyrosine kinases, which upon ligand 
addition auto-activate and phosphorylate the receptor (55).  This however, is not the case 
with IL-2 and most multi-subunit cytokine receptors.   
 
After receptor dimerization, the tyrosine kinases Janus kinase 1 (Jak1) and Jak3 are recruited 
from the cytosol and non-covalently attach to the Box 1 and Box 2 motifs on the IL-2Rβ and 
γc, respectively (16, 28).  Being in close proximity, the Jak kinases are able to sequentially 
transactivate each other via tyrosine phosphorylation (68).  Once activated, it was found that 
the Jak kinases phosphorylate six specific tyrosine residues on the IL-2Rβ resulting in full 
activation of the receptor complex for signaling − four of which (Y-338, Y-355, Y-358 and 
Y-361) are located within the acidic-region and the additional two (Y-392 and Y-510) in the 
proline-rich region (13, 14) (Figure 1.3 a).  Once phosphorylated, these specific, conserved 
tyrosine sites on the receptor subunit serve as docking sites for signaling proteins.  
 
Other non-receptor tyrosine kinases, such as Syk, Lck and Fyn, bind to these 
phosphotyrosine sites and are poised to activate further signaling proteins that may bind to 
IL-2Rβ (30, 34, 35, 61).  There are three major cascades involved with IL-2 signaling that are 
responsible for the survival and proliferation of T cells: Jak/STAT, Ras/extracellular signal-
regulated kinase (Erk) and phophatidylinositol 3-kinase (PI3K)/Akt (13); each of these 
pathways is discussed in greater detail in Chapter 2.  In general, signals are transmitted 
through a cascade by phosphorylation or conformational changes, involving multiple signal 
transducers and adapters, leading to either the amplification or attenuation of a cellular 
consequence (7). 
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IL-4 function 
 
IL-4 is a multifunctional cytokine produced by activated TH2 cells, mast cells and basophils.  
In addition to its function in T cell differentiation, IL-4 plays several other decisive roles in 
the immune response.  IL-4 can stimulate B cells to proliferate, induce their class-switching 
of immunoglobulin to IgE and IgG, and enhance their expression of class II MHC molecules 
(36, 37).  During inflammation, IL-4 cooperates with tumor necrosis factor (TNF) to induce 
expression of vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells, and it 
downregulates the expression of E-selectins.  This shift in adhesion molecule expression by 
IL-4 is thought to favor the recruitment of T cells and eosinophils into an inflammation site 
and aid in healing (3).  For millions of people, the overproduction of IL-4, especially in the 
respiratory system, leads to airway hyper-reactivity and the development of asthma.  Asthma, 
generally triggered by allergic reactions, perfectly illustrates why it is critical to maintain a 
proper balance of cytokines within the body (5, 64). 
 
IL-4 receptor structure  
 
The IL-4 receptor is a heterodimer composed of the 140 kDa IL-4Rα and the γc subunit 
(Figure 1.3 b).  The IL-4Rα binding epitope contains a series of acidic residues that attracts 
the large positively charged areas on the IL-4 surface created by several basic residues (36).  
This attraction is responsible for the extremely high affinity observed for IL-4Rα and its 
ligand (Kd = 20 pM) (39). 
 
Over several years, four distinct domains within the IL-4Rα were discovered and 
characterized.  The membrane proximal region contains the conserved “Box 1” and “Box 2” 
sequences, which serve as a docking site for Jak1.  The second domain, the insulin/IL-4 
receptor (I4R) domain, is critical for the initiation of proliferative and anti-apoptotic signals. 
The gene-activating motif, the third region, is responsible for activating transcription factors 
that alter gene expression.  The last section contains the immunoreceptor tyrosine-based 
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inhibitory motif (ITIM), which is responsible for the downregulation of the proliferative 
signals induced by IL-4 (45). 
 
As with the IL-2Rβ, it was determined that the IL-4Rα subunit contains several specific 
tyrosine residues that become phosphorylated and serve as docking sites for signaling 
proteins.  The I4R domain contains one of the five tyrosine sites (Y-497), the gene-activating 
motif includes three conserved residues (Y-575, Y-603 and Y-631) and the remaining 
tyrosine site (Y-713) lies within the ITIM region (39) (Figure 1.3 b). 
 
IL-4 signaling initiation 
 
In a similar manner as IL-2, the binding of IL-4 causes the heterodimerization of its receptor 
subunits.  The dimerization of the cytoplasmic regions is essential and sufficient for the 
initiation of IL-4 receptor signaling (60).  Neither the IL-4Rα or the γc chain possesses 
endogenous kinase activity, therefore, the IL-4R requires receptor-associated kinases for the 
initiation of signal transduction.  The non-receptor tyrosine kinases Jak1 and Jak3 bind to 
either the Box 1 or Box 2 motifs on the IL-4Rα and γc, respectively, followed by their 
transactivation.  Very quickly after IL-4 engagement, Jak1 phosphorylates the five conserved 
tyrosine residues on the IL-4Rα, thus activating the receptor complex (49).  Additional 
tyrosine kinases, Lck and Fyn for example, may also be recruited from the cytosol, bind to 
the IL-4Rα and help to activate other signaling proteins (60).  IL-4 efficiently activates two 
major signaling cascades in T and B cells that lead to cellular proliferation; the Jak/STAT 
and PI3K/Akt pathways (21, 39).  The IL-4R is unique among cytokines and growth factors 
in the respect that it does not incite the Ras/Erk signaling cascade, as will be further 
discussed in Chapter 2 (47, 53, 66, 67). 
 
IL-2 and IL-4 induced synergy
 
IL-2 and IL-4 are both T cell growth factors that employ many of the same mechanisms to 
accomplish their functions.  When these cytokines are simultaneously exposed to T cells, 
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they exert a synergistic effect that enhances the rapid expansion of the target cells (48, 63).  
Synergy may be accomplished by altering the balance of the intracellular signaling pathways 
involved in T cell proliferation and/or survival.  At the same time, IL-2 and IL-4 receptors 
must compete for a common pool of γc subunits, suggesting the presence of an antagonistic 
relationship at high ligand levels.  It is believed that this modification is in part due to the 
downregulation in functional IL-2R complexes by IL-4, owing to the fact that both cytokines 
utilize the γc subunit (4, 10). 
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CHAPTER 2 
 
INTRODUCTION AND OVERVIEW PART 2: 
SIGNALING PATHWAYS STIMULATED BY IL-2 AND IL-4 
 
2.1  BACKGROUND 
The IL-2 receptor mediates three important signaling pathways:  Jak/STAT5, PI3K/Akt and 
Ras/Erk.  IL-4 stimulates the Jak/STAT6 and PI3K/Akt pathways but is unique among 
cytokines and growth factors in that it does not employ the Ras/Erk cascade.  In this chapter 
each of these cascades is discussed with regard to the proteins involved, activation and 
regulation mechanisms and downstream targets.  Figure 2.1 summarizes the pathways 
induced by IL-2 and IL-4 in T cells and illustrates how sequential activation of signaling 
proteins leads to clonal expansion. 
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Figure 2.1  IL-2 and IL-4 induced signaling pathways  a)  Following IL-2/IL-2R ligation, 
three signaling cascades are activated – the Jak/STAT5, the Ras/Erk and the PI3K/Akt 
pathways.  These pathways cooperate to induce the cell cycle progression and survival 
necessary to achieve rapid proliferation and differentiation, also known as clonal expansion.  
b)  Following activation of the IL-4R, two major signaling pathways are activated leading to 
cell cycle progression, differentiation and survival – the Jak/STAT6 and the PI3K/Akt 
cascades.  IL-4 is unique among cytokines in the respect that it does not employ the Ras/Erk 
cascade. 
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2.1.1  The Jak/STAT pathway
 
Overview
 
The Jak/STAT pathway is one of the most direct and simplistic cascades known to date in 
signal transduction.  STATs (signal transducers and activators of transcription) are 
transcription factors that bind to phosphotyrosine sites on cytokine receptors, become 
activated via tyrosine phosphorylation by Jaks, dimerize and translocate to the nucleus, 
where they induce gene expression (31, 66, 67).  STATs are also capable of triggering the 
activation of additional transcription factors, promoting progression through the cell cycle 
and initiating differentiation (112).  The Jak/STAT pathway induces several negative 
regulatory mechanisms, without which the established signals would lead to uncontrolled 
growth and differentiation (104, 161). 
 
The Jak family
 
Four mammalian protein tyrosine kinases have been identified in the Jak family: Jak1, Jak2, 
Jak3 and Tyk2 (66).  Jak1, Jak2 and Tyk2 are widely expressed and are used in the activation 
of several cytokine receptors, whereas Jak3 expression is highly regulated and binds solely to 
γc.  Consequently, as seen with the γc subunit itself, inactivating mutations in Jak3 have been 
linked to the development of SCID, marked by a dramatic reduction in the number of 
responsive lymphocytes (95, 134).  Mutational studies in Jak family proteins have shown 
severe immunodeficiencies, non-responsiveness to cytokine stimulation and even death, 
making it clear that these four kinases possess non-redundant functions in vivo (80). 
 
Analysis and comparison of Jak family sequences revealed seven regions of high homology, 
JH1-JH7.  Although the biological importance of all these regions has not yet been fully 
elucidated, the function of several of these domains are well characterized.  After noting that 
JH1 is critical for proper Jak activity, it was discovered to contain the kinase domain.  Jak 
proteins are unique in containing two kinase domains, with JH2 representing a pseudokinase 
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domain required for full catalytic activity (152).  The JH3-JH4 regions share some similarity 
with Src Homology-2 (SH2) domains, but lacks phosphotyrosine binding ability.  JH4-JH7 
has been denoted the FERM (Four-point-one, Ezrin, Radixin, Moesin) domain and mediates 
the association of Jak with other proteins; JH7 binds specifically to the Box 1 motif in 
receptor subunits, while JH4-JH6 allows for associations with other Jak or non-receptor 
kinases (116, 152). 
 
The role of Jaks in cytokine signaling
 
IL-2 and IL-4 receptors both lack intrinsic tyrosine kinases, so they must associate with non-
receptor kinases to initiate signaling.  Inactive Jak1 and Jak3 have been shown to quickly 
become coupled with IL-2Rβ or IL-4Rα and γc, respectively, following IL-2/IL-4 stimulation 
(116), although there is still some debate about whether these kinases are recruited from the 
cytosol or are pre-coupled to the receptor subunits in an inactive state.  The JH7 domain of 
Jak proteins associates with the membrane proximal, proline rich conserved regions in the 
cytokine receptors, termed Box 1 or Box 2.  This is the only known portion of the receptor 
where Jak1 and Jak3 will bind, and deletion of this region abrogates cytokine-induced 
signaling (66, 70, 106, 150). 
 
Dimerization of the cytoplasmic domains of the receptor chains is required for signaling and 
is proposed to bring Jaks into sufficient proximity to allow for cross-phosphorylation and 
kinase activation.  The Jaks in IL-2 and IL-4 induced signaling are turned on sequentially, 
with Jak3 activating Jak1 via tyrosine phosphorylation (175).  Within the kinase domain of 
Jak1 and Jak3 there exists an activation loop that is regulated by two conserved tyrosine 
residues: Y1033 and Y1034 for Jak1 and Y975 and Y976 for Jak3 (91).  In the case of Jak1, 
phosphorylation of Y1033 by Jak3 is required for kinase activation, while the second tyrosine 
is dispensable.  Jak3 is unique in the respect that the activation-loop tyrosines are not 
absolutely required for catalytic activity.  Even if Y975 and Y976 are not phosphorylated, 
Jak3 retains a low basal level of kinase ability, though it is greatly diminished compared to 
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full Jak3 activation (91).  This explains how Jak3 is capable of turning on Jak1 following 
cytokine stimulation, prior to phosphorylation of its own conserved tyrosine residues. 
 
Following its activation, Jak1 is primarily responsible for priming the receptor complex by 
phosphorylating the conserved tyrosine residues, on IL-2Rβ or IL-4Rα (66).  These 
phosphotyrosine residues can serve as docking sites for other protein tyrosine kinases, which 
bind to the receptor using their Src homology-2 (SH2) domains.  Once a kinase is bound to a 
phosphotyrosine residue, Jak1 is already poised to turn on these proteins via phosphorylation 
(69, 175).  These additional kinases play a crucial role in intracellular signaling by 
phosphorylating and activating other proteins that may bind to the receptor.   
 
Another responsibility of the Jak family is the phosphorylation of the receptor-bound STAT 
transcription factors.  STATs are the preferential substrate of Jaks, and will be 
phosphorylated by these specific kinases before any other proteins present (67, 116).  The 
recruitment and full catalytic activity of Jak1 and Jak3 are essential for IL-2 and IL-4 
induced signals; if either of these kinases is deleted or mutated, all of the ensuing signal 
transduction is abolished (106). 
 
The STAT family
 
To date, the STAT family of transcription factors consists of seven members; STAT1, 
STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6 (64).  Each STAT protein has 
critical and non-redundant biological functions that operate through the cytokine receptor 
superfamily.  Most of the STAT transcription factors mediate functions that influence the 
response of the immune system, underscoring the importance of these proteins not only for 
cytokine-stimulated signal transduction but for pathogen removal and maintenance of 
homeostasis (64). 
 
Analysis of the STAT family has revealed six conserved functional domains.  First, the 130 
N-terminal amino acids represents a domain believed to regulate STAT nuclear translocation 
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(80).  The coiled-coil motif follows, consisting of four α-helices that when folded together 
form a large, predominantly hydrophilic surface that can interact with other helical proteins.  
Amino acids 320-480 form the DNA-binding domain (DBD), which contains the few 
residues capable of associating with DNA (116).  Next is a small linker area that connects the 
DBD to the SH2 domain.  The SH2 domain is an essential feature for protein activation and 
function, as it mediates both receptor association and dimerization.  The STAT family is the 
only group of transcription factors that requires a SH2 domain for operation (31).  Finally, at 
the carboxyl terminus the transcriptional activation domain (TAD) is located, which contains 
two conserved residues, one tyrosine and one serine, that must become phosphorylated for 
transcriptional activity of STAT proteins (31, 80).    
 
Following cytokine stimulation and receptor activation, the STAT proteins are recruited to 
the receptor through their SH2 domains, whereupon they are tyrosine phosphorylated by the 
receptor-bound Jaks (116).  Research has shown that Jaks must be present for 
phosphorylation of STATs to occur, suggesting that STAT proteins are a direct substrate of 
the Jaks (67).  STATs may then dissociate from the receptor and dimerize through reciprocal 
phosphotyrosine/SH2 interactions.  These dimers may then migrate to the nucleus, where 
they bind to DNA and induce target gene upregulation.  Homodimers and heterodimers (in 
the case of STAT5a and STAT5b), but not monomers, are capable of associating with DNA 
(31, 116).  While phosphorylation of the tyrosine residue within the TAD is necessary for 
dimerization and translocation of STATs, it has been found that serine phosphorylation is 
only required for maximal transcriptional activity.  Serine phosphorylation of the STAT 
dimers is thought to stabilize the complex and prevent the proteins from uncoupling (163).  
 
STAT5 
 
It is believed that the STAT family of proteins originated from an initial STAT gene that 
underwent duplication multiple times.  Nowhere is this more evident than when comparing 
STAT5a and STAT5b, which are over 96% homologous (111, 136).  STAT5 was originally 
discovered as a transcription factor important in prolactin-dependent mammary gland 
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development (64).  It has since been determined that STAT5 plays an important role in the 
immune system, regulating B cell development, directing macrophage response to 
inflammation, and inducing T cell expansion (80, 116).  Transcriptional activity of STAT5 is 
stimulated in T cells following treatment with IL-2 and has been proven to be critical for IL-
2-stimulated cell cycle progression and proliferation (153).  
 
Following activation of the IL-2 receptor complex, STAT5 is recruited from the cytosol and 
binds to IL-2Rβ through one of two specific phosphotyrosine sites, Y-392 or Y-510 (45, 49).  
These two tyrosine residues are functionally redundant; only one site is required to elicit the 
full proliferative effect induced by STAT5 (43).  Once bound to the receptor, Jak1 
phosphorylates the conserved tyrosine residue located within the TAD sequence - Y-694 in 
STAT5a and Y-699 in STAT5b.  After phosphorylation, the activated STAT proteins may 
dissociate from their docking sites, dimerize, translocate to the nucleus and bind to certain 
DNA motifs (89). 
 
Once in the nucleus, STAT5 plays an important role in regulating transcription of target 
genes that are critical for T cell clonal expansion.  One of the best characterized responses to 
STAT5 is the induction of the IL-2Rα gene.  Gene activation leads to the increased presence 
of high affinity IL-2 receptors, which helps promote the T cell response to IL-2 in an 
autocrine fashion (6).  STAT5 also can control the transcription of several genes that are 
critical for cell cycle progression.  Through knock-out studies, it has been shown that 
STAT5a/b controls the induction of cyclin D1, cyclin D2, cyclin D3 and cdk6, all of which 
have essential roles in cell cycle progression.  Translation of several proteins that are 
required for the proliferative response can also be induced by STAT5, including c-myc, Bcl-x 
and Bcl-2 (92).  STAT5 is also responsible for the upregulation of cytokine-inducible SH2-
containing (CIS) proteins, which negatively regulate STAT activation and prevent excessive 
STAT-mediated signaling in T cells (89).   
 
As with all intracellular signaling proteins that play a role in proliferation, lack of STAT5 
negative regulation contributes to cancer development (2, 167).  Several regulatory 
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mechanisms are in place to help police the Jak/STAT5 pathway.  Following ligand binding, 
the cytosolic protein-tyrosine phosphatase, SH2-containing protein 2 (SHP-2), is recruited to 
the IL-2Rβ, where it is capable of dephosphorylating and deactivating both Jak1 and STAT5 
(168).  Further, as previously mentioned, STAT5 induces the expression of CIS-1, which 
negatively regulates Jak/STAT signaling by associating with Jak1 and blocking its catalytic 
activity.  Additionally, CIS-1 can bind to the IL-2Rβ on the same phosphotyrosine sites as 
STAT5, reducing STAT5 activation by competitive inhibition (5, 101).  A third mediator of 
STAT5 regulation is suppression of cytokine signaling 3 (SOCS-3), a member of a 
phosphatase family that regulates cytokine signaling.  After IL-2 stimulation, SOCS-3 
associates with the receptor, becomes activated by Jak1 and dephosphorylates receptor-
bound STAT5, thus suppressing STAT5 induced gene expression (24).  All of these cellular 
mechanisms in combination are capable of regulating STAT5 activation and cellular 
proliferation in response to IL-2, helping to maintain homeostasis and avoid tumorigenesis. 
 
STAT6 
 
STAT6 was the most recently discovered member of the STAT family of transcription 
factors (64).  By knocking out its expression, it was revealed that STAT6 is required for T 
cells to respond to IL-4 and differentiate into TH2 subsets and for B cells to engage in class 
switching and IgE production.  STAT6-null mice also express a reduced pathology for 
asthma development and tumor formation, illuminating the role of IL-4 and STAT6 in these 
diseases (64, 80, 116). 
 
Following IL-4 stimulation and receptor activation, STAT6 molecules translocate from the 
cytosol to the IL-4Rα, where they bind to the conserved phosphotyrosines Y-575, Y-603 and 
Y-631 (59, 159).  After associating with the receptor, STAT6 monomers are tyrosine 
phosphorylated and activated by Jak1 on the conserved residue Y-641, after which they may 
dissociate from the receptor, dimerize, and migrate to the nucleus to activate transcription of 
target genes (165).   
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Activated, dimerized STAT6 is capable of both inducing the expression of and activating 
several other transcription factors to aid in signal transduction, including GATA-3, AP1, 
NFAT, NFκB and c-maf (52).  The general transcription factor hierarchy in the IL-4 
signaling cascade is as follows: STAT6 optimally induces the expression of GATA-3, which 
in turn induces c-maf, AP1, NFAT and NFκB in the nucleus.  Once co-localized, this 
entourage of transcription factors selectively binds to target DNA segments and together 
initiate extensive gene expression (56, 57, 118). 
 
The primary gene target of this collection of transcription factors is the IL-4 promoter, which 
contains necessary binding sites for NFAT, NFκB, STAT6 and c-maf.  Additionally, the IL-4 
3' enhancer region specifically requires GATA-3 and NFAT association to initiate 
transcription (87, 174).  Beyond IL-4 ligand secretion, STAT6 also regulates the transcription 
of several other genes.  A STAT6 DNA binding site has been identified within the promoter 
of the IL-4Rα gene, demonstrating how STAT6 contributes to IL-4 autocrine signaling (82).  
STAT6 also factors into IL-4-induced T cell cycle progression and is required for normal 
proliferation of T lymphocytes.  It has been demonstrated that dimerized STAT6 inhibits the 
activity of p27kip, a protein that downregulates cdk2 and thus negatively regulates the G1 to 
S phase transition (73). 
 
As with all members of the STAT family, STAT6 must be carefully regulated to prevent 
excessive gene transcription.  The c-terminus of the IL-4Rα contains an inhibitory ITIM 
motif, where SHP-1/2 may bind to Y-713 and dephosphorylate both the IL-4Rα and any 
local STAT6 (75, 79).  As in IL-2 receptor signaling, the SOCS family plays an important 
role in inhibiting IL-4 signal transduction via STAT6.  In the IL-4 system SOCS-1, and to a 
lesser extent SOCS-3, are capable of potently blocking the Jak1 and STAT6 response (93, 
165).  Finally, gene induction by STAT6 can be blocked by B cell lymphoma-6 (Bcl-6), a 
powerful transcriptional repressor that recognizes and associates with the same DNA 
elements as STAT6, competing for specific DNA binding sites.  Interestingly, the 
transcription of Bcl-6 is initiated by STAT6 through a negative feedback loop; as STAT6 
activity decreases, the expression of Bcl-6 correspondingly diminishes (34, 35).  The control 
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of the signaling and gene induction following Jak/STAT6 activation is crucial in the 
regulation of T cell growth and differentiation in the presence of IL-4. 
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2.1.2  The PI3K pathway
 
Overview
 
The phosphoinositide 3-kinases (PI3Ks) are a well characterized, conserved family of lipid 
kinases, which also possess a less understood serine-threonine protein kinase activity. A great 
variety of stimuli including, antigens, costimulatory molecules, growth factors and cytokines 
are all able to recruit and activate PI3K at the plasma membrane, upon which 3΄ 
phosphoinositide (PI) lipids are produced (44).  The lipid products of PI3K are important 
second messengers that bind and activate an array of cellular target proteins, which control 
cell proliferation, differentiation, survival, migration and metabolism (44, 117).  As PI3K 
impacts numerous cellular responses, it is not surprising that activating mutations or 
overexpression of PI3K is linked with both cancer and leukemia (123, 156). 
 
Structure and activation of PI3K
 
The PI3K family members are subdivided into four classes based upon their structural 
characteristics and substrate specificities: class Ia, Ib, II and III.  Class Ia PI3Ks are activated 
in response to cytokine stimulation, and hence will be the only class discussed here (155).  
Class Ia PI3Ks are heterodimeric proteins comprised of a regulatory subunit and a catalytic 
subunit, which are constitutively associated.  
 
There are five different isoforms of the regulatory subunit: p85α, p55α, p50α, p85β and 
p55γ; of these, p85α is the prototype.  The p85α regulatory subunit consists of an N-terminal 
SH3 domain followed by a BcR homology (BH) domain that is flanked by proline rich 
sequences.  The remaining structure of p85α is comprised of two SH2 domains, used to 
associate PI3K with tyrosine-phosphorylated proteins, separated by an “inter-SH2” domain 
that is responsible for binding to the catalytic subunit (155, 166).  There are three genes for 
the p110 catalytic subunit of the type Ia class- p110α, p110β and p110δ.  Structural analysis 
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of the class Ia p110 catalytic domain revealed an N-terminal p85 binding domain, followed 
by a Ras binding domain, a C2 domain and the PI3K catalytic domain (76). 
 
Prior to PI3K association with a phosphorylated protein, the p85 regulatory subunit inhibits 
the catalytic activity of p110.  At the same time, p85 also stabilizes and prevents the 
degradation of p110 (169).  The two SH2 domains of p85 can bind to certain 
phosphotyrosine sites, which induce a conformational change that allows the catalytic site of 
PI3K to be exposed.  This change releases the inhibitory role p85 has over p110, and allows 
for full catalytic activity of PI3K (29, 68).  p85 may also be tyrosine phosphorylated by Src 
family kinases, such as Lck or Fyn, on Y-688, which stabilizes this conformational changes 
and prolongs PI3K activation (158).  
 
Following IL-2 stimulation, the IL-2R complex becomes phosphorylated and primed for 
induction of signaling cascades.  Prior to receptor phosphorylation, p85 will not associate 
with the receptor in any way nor will PI3K become activated (103, 149).  There are two 
routes for PI3K activation in response to IL-2 stimulation, either through association with the 
collective receptor complex or through binding to Ras-GTP (68), the latter will be discussed 
in a following section.  Because the IL-2R lacks direct binding sites for PI3K, how this 
cascade is activated remains somewhat controversial.   
 
It is established that p85 can associate with and be phosphorylated by tyrosine kinases that 
are bound to the IL-2Rβ.  For example, both Lck and Fyn will preferentially bind to Y-355 or 
Y-361 on the IL-2Rβ and serve as a docking site for and activator of PI3K (54, 74, 145).  The 
mechanism in which PI3K can be recruited and induced through a Shc/Grb2/Gab2 pathway 
is also well understood and documented (58).  Shc is an adapter protein that binds to Y-338 
of the IL-2Rβ and is capable of concurrently associating with other adapter proteins 
including Grb2 and Gab2 (Grb2 associated binding protein 2).  The strong affinity of p85 for 
Gab2 tends to attract PI3K to this complex where upon binding PI3K is activated (21, 58, 
113).  
 
 30
How PI3K is activated following IL-4 stimulation is a well studied and understood process.  
Following receptor phosphorylation, the 170 kDa insulin receptor substrate-1 (IRS-1) binds 
to the phosphotyrosine Y-497 of the IL-4Rα and is phosphorylated by Jak1 (78, 160).  IRS-1 
has approximately 20 conserved tyrosine residues that can be phosphorylated by Jak1, 
making it capable of serving as a hub for several protein-protein interactions, including the 
recruitment of the PI3K regulatory subunit (143).  Inactive PI3K translocates from the 
cytosol to the phosphorylated IRS-1 protein, where the p85 subunit binds via its dual SH2 
domains, undergoing the necessary conformational change for PI3K activation (36, 170). 
 
3΄ phosphoinositide (PI) lipids  
 
The major lipid substrate of active PI3K is phosphatidylinositol(4,5)biphosphate, PI(4,5)P2.  
Class Ia PI3Ks phosphorylate this membrane lipid at the 3΄ position of its inositol ring, 
producing phosphatidylinositol(3,4,5)triphosphate, also known as PI(3,4,5)P3 or PIP3 (85, 
154) (Figure 2.2).  Although PI3K preferentially catalyzes the phosphorylation of PI(4,5)P2, 
it will also convert PI(4)P to PI(3,4)P2 or PIP2.  PIP2 and PIP3 are usually absent in quiescent 
cells, then appear within minutes of PI3K stimulation (61, 128).  PIP3 lipids act as second 
messengers and recruit numerous signaling proteins that contain pleckstrin homology (PH) 
domains, due to the strong affinity between PH domains and PIP3 (124).  Target proteins 
include Vav, TEC family kinases and p70 S6kinase, which are activated following IL-2 
stimulation and help regulate proliferation (8, 108).  However, the two principal effectors of 
PI3K signaling are Akt and 3-phosphoinositide-dependent protein kinase 1 (PDK1), which 
both have wide-ranging effects on cell behavior.   
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Figure 2.2  PI3K activation by the IL-2 receptor system  The p85 regulatory subunit of 
class IA PI3Ks associates with the IL-2 receptor complex through the utilization of a non-
receptor kinase, such as Lck.  The p110 catalytic subunit of PI3K catalyzes the reaction of 
PI(4,5)P2 to PI(3,4,5)P3 in the plasma membrane   The creation of the lipid messenger PIP3 is 
highly regulated by the phosphatase PTEN. 
 
In order to maintain homeostasis, PI3K signaling must remain strictly regulated.  In an effort 
to maintain this balance, several mechanisms are in place to control the levels of both active 
PI3K and the lipid secondary messenger, PIP3.  The phosphatase SHP-2 controls PI3K-
induced signaling by dephosphorylating Y-668 in the regulatory domain, increasing the 
likelihood that PI3K will dissociate from the receptor (29).  Two proteins play an important 
role in the regulation of PIP3 levels: PTEN (phosphates and tensin homologue deleted on 
chromosome ten) and SHIP-1 (SH2-domain containing inositol polyphosphatases-1) (7).  
 
PTEN was originally identified as a tumor suppressor, due to the fact that a deletion or 
mutation in PTEN can promote the development of cancer (37, 135).  PTEN is a dual 
specificity phosphatase that can target either proteins or lipids, with its main substrate being 
3′ phosphorylated phosphoinositides such as PIP3.  PTEN hydrolyzes PIP3 to PI(4,5)P2, 
specifically dephosphorylating the 3΄ position of the inositol ring and reversing the actions of 
PI3K (96, 144) (Figure 2.2).  SHIP is a 145 kDa phosphatase that is activated by a wide 
variety of stimuli, including IL-2 and IL-4, and aids in controlling cellular survival and 
proliferation (98).  SHIP-1 substrates include both signaling proteins and the lipid messenger 
PIP3.  In contrast to PTEN, SHIP removes the 5΄ phosphate from the inositol ring of PIP3 to 
generate PI(3,4)P2, thus hindering PI3K dependent signaling (42, 131). 
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The role of PDK1 in Akt activation
 
Akt is a proto-oncogene and serine/threonine kinase that plays a central role in cell survival 
and proliferation.  Akt is perhaps the most important, and definitely the most studied, 
downstream target of PI3K, because it influences the activation of numerous other signaling 
proteins (11).  The amino acid sequence of Akt reveals a very simple structure, consisting of 
an N-terminal PH domain, a catalytic region and a C-terminal regulatory domain (11).   
 
The signaling pathway involved in Akt activation is fairly straightforward, though it contains 
multiple steps.  Briefly, Akt binds to PIP3 at the plasma membrane through its PH domain, 
causing a conformational change in the protein that relieves an autoinhibition of the active 
site (18).  PIP3 is also responsible for activating PDK1, another serine/threonine kinase.  
With these two kinases in close proximity, PDK1 threonine phosphorylates Akt on T-308, 
which lies in the activation loop (3, 13).  Following phosphorylation of T-308, Akt requires a 
serine phosphorylation on S-473 for full functionality (16).  Determining which kinase is 
responsible for S-473 phosphorylation has proved to be a major challenge.  It has been 
proposed that a second kinase, PDK2, exists to complete this task, though this protein has not 
been identified (3).  It has also been suggested that PDK1 phosphorylates both Akt sites 
sequentially (147).  
 
PDK1 was first discovered in the context of Akt signaling, however its importance in the 
activation of other signaling proteins has since been further elucidated.  PDK1 regulates the 
activity of several other protein kinases, including protein kinase A (PKA), protein kinase C 
(PKC), p90RSK and p70 S6kinase (83, 147).  As a key regulator of these kinases and of Akt, 
with each exhibiting different cellular functions, PDK1 activation illustrates how PI3K can 
impact so many cellular processes. 
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Akt functions and targets
 
Through serine/threonine phosphorylation, Akt regulates several signaling proteins, all of 
which impact one of two cellular outcomes - cell survival or proliferation.  While all three 
signaling pathways involved in the IL-2 response contribute to cell cycle progression and 
proliferation, the PI3K/Akt pathway is solely responsible for inhibiting apoptosis, or 
programmed cell death.  First and foremost, Akt activates the B cell lymphoma 2 (Bcl-2) 
family, which is responsible for regulating apoptotic pathways.  The two main pro-survival 
proteins, Bcl-2 and Bcl-xL, prevent apoptosis by associating with the mitochondria and 
maintaining the membrane integrity (26).  If the protein cytochrome c is released from the 
mitochondrial membrane, it will activate Apaf-1, which then binds to and activates caspase-
9, triggering apoptosis (26).  Both Bcl-2 and Bcl-xL are activated in an Akt-dependent 
manner and are necessary in preventing programmed cell death (1, 22, 54, 90).   
 
Akt is also able to restrict pro-apoptotic members of the Bcl-2 family, such as Bax and Bad.  
Upon activation, Bax associates with the mitochondria, where it binds to the membrane and 
advances the release of cytochrome c; however, once Akt phosphorylates Bax, it becomes 
sequestered in the cytosol (151).  Bad encourages apoptosis by forming a heterodimer with 
Bcl-xL or Bcl-2, preventing the pro-survival proteins from maintaining the stability of the 
mitochondrial membrane.  After Akt phosphorylates Bad on S-136 and S-112, it becomes 
bound and isolated by the adapter protein 14-3-3  (32, 33).  
 
Additionally, Akt can directly phosphorylate caspase-9 on S-183 and S-196, blocking 
caspase-9 self cleavage, which in turn inhibits induction of the caspase cascade and apoptosis 
(17).  Similarly, it has been found that caspase-3 activity can be reduced by a PI3K-
dependent mechanism, preventing DNA fragmentation (14).  Lastly, Akt dependent 
activation of NFκB, which leads to cell survival, has been well studied.  In the cytosol, NFκB 
is dimerized with a class of inhibitory proteins called IκBs, which prevents NFκB from 
migrating to the nucleus and initiating gene transcription.  Following the activation of PI3K, 
IκB is phosphorylated by Akt, causing a conformational change that leads to the release of 
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NFκB (72, 132).  NFκB is then free to upregulate the expression of several anti-apoptotic 
proteins and assist in maintaining cell survival (41). 
 
The second major role of Akt target proteins is to stimulate proliferation by promoting cell 
cycle progression.  Cell cycle progression is brought on by a two wave response consisting of 
an immediate burst of signaling followed by the activation of cyclin dependent kinases 
approximately twelve hours later (71).  One downstream target of Akt that promotes cell 
cycle entry is E2F, a crucial regulator whose activation is required to pass the G1 to S 
checkpoint (12).  Secondly, the transcription factor c-myc is induced following Akt 
activation.  Although the exact mechanism behind the c-myc response is not understood, it is 
known that its expression enhances the progression through the cell cycle (1, 23).  
 
p27kip is a cell cycle inhibitor that binds to cyclin dependent kinases and blocks progress 
through the cell cycle.  Akt opposes this interference by phosphorylating p27kip on T-157, 
causing it to be sequestered in the cytosol (25, 140).  In a similar fashion, the obstruction of 
cell cycle progression brought on by the transcription factor FoxO is negated in a PI3K-
dependent manner.  After phosphorylation on T-24, S-253 and S-316 by Akt, nuclear 
translocation is halted, preventing the transcription of FoxO target genes (137, 142).  While 
the number of downstream signaling proteins induced by PI3K/Akt are too numerous to 
discuss here, the aforementioned targets are some of the most critical in promoting survival 
and cell cycle progression. 
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2.1.3  The Ras/Erk cascade
 
Overview
 
Ras/Erk is the third major signaling pathway stimulated by IL-2, but, importantly, it is not 
activated in response to IL-4.  Ras/Erk is also known as the mitogen-activated protein kinase 
pathway (MAPK) due to the fact that Erk (also known as MAPK) is the final kinase activated 
in the cascade.  Ras belongs to a large superfamily of small GTPases that are critical for 
transmitting intracellular signals.  Following IL-2R activation, Ras becomes activated, 
triggering a signaling cascade of protein kinases that include Raf, MEK and Erk.  Activated 
Erk targets several transcription factors that influence a plethora of cellular fates (81).  In 
response to IL-2, Ras/Erk regulates cell differentiation, proliferation, apoptosis and cell cycle 
progression in T cells (53, 55, 86).  A significant percentage of human cancers are caused by 
activating mutations in the Ras/Erk pathway, leading to unregulated cell growth and 
differentiation (19, 102). 
 
Ras: The GTPase family and activation 
 
Ras is a member of the superfamily of small GTPases, whose activation states depend on the 
species of guanine nucleotide bound.  Active GTPases are bound to guanosine triphosphate 
(GTP), whereas inactive forms are associated with guanosine diphosphate (GDP).  In 
quiescent cells, most small GTPases are usually coupled with GDP, making them inactive.  
Following stimulation, the removal of GDP and the loading of GTP is facilitated by a class of 
enzymes known as guanine nucleotide exchange factors (GEFs).  Since small GTPases have 
a low intrinsic GTPase activity, GTPase accelerating proteins (GAPs) are utilized in the 
hydrolysis of GTP to GDP, which completes the activation cycle and is crucial in the 
regulation of Ras and other GTPases (10, 100). 
 
Four isoforms of Ras exist, H-Ras, N-Ras and two K-Ras proteins, which are nearly identical 
except for the hypervariable region at the C-terminus.  This variability causes the Ras 
proteins to differ in their membrane targeting sequences, which affects their localization.  H-
Ras is the isoform most studied and is generally activated in response to growth factors or 
cytokines (139).  
 
Stimulation of the Ras/Erk pathway by IL-2 begins with the recruitment and tyrosine 
phosphorylation of the adapter protein Shc, which binds to the IL-2Rβ solely at Y-338 
through its phosphotyrosine binding (PTB) domain.  Shc is a unique adapter protein in that it 
contains both a PTB and an SH2 domain, making it capable of coupling several proteins 
simultaneously (40, 77, 125).  Once Shc is bound the IL-2Rβ, it is phosphorylated on Y-239 
and Y-317, priming it to serve as a docking protein for other signaling molecules (15, 171).  
Grb2 serves as a linker protein that constitutively binds the GEF Son of Sevenless (Sos) 
through one of its two SH3 domains.  The Grb2/Sos dimer then couples with the 
phosphorylated, receptor-bound Shc bringing the GEF into close proximity with the 
membrane-bound Ras-GDP, promoting the formation of Ras-GTP (39, 50, 88, 119) (Figure 
2.3). 
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Figure 2.3  IL-2 induced activation and regulation of Ras  Following IL-2 receptor 
activation the receptor-bound adapter protein Shc couples with the Grb2/Sos dimer.  Sos, a 
known GEF, dislodges the bound GDP from the inactive Ras, which allows for rapid loading 
of GTP, stimulating Ras activation.  RasGAP proteins regulate the level of functional Ras-
GTP by stimulating the hydrolysis of GTP to GDP, thus returning Ras to its inactive GDP-
bound state. 
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There is a possibility that another step is involved in the activation of Ras, though it remains 
controversial.  This step involves the tyrosine phosphatase SHP-2, which may be required to 
achieve full activation of Ras (99).  After SHP-2 binds either directly to Shc or indirectly 
through the adapter protein Gab2, it becomes activated by a two-step mechanism.  Once 
SHP-2 binds and both SH2 domains are engaged by phosphotyrosines, the two tail tyrosine 
residues, Y-542 and Y-580, become phosphorylated by neighboring kinases, activating the 
phosphatase (94).  SHP-2 now can serve as a binding site specifically for the Grb2/Sos 
dimer, positively modulating the level of Ras activation.  It has also been suggested that the 
phosphatase activity of SHP-2 is somehow involved in the recruitment and activation of Ras, 
though this mechanism has never been fully clarified (9, 114).  Once GTP-bound, Ras is 
proficient in recruiting its target proteins to the membrane and initiating its signaling cascade.  
 
Downstream signaling of Ras
 
The first target of Ras in the Ras/Erk pathway is the serine/threonine kinase Raf.  Exactly 
how Raf is activated following its interaction with Ras-GTP is still under scrutiny (81).  
What is clear is that Raf activation involves membrane recruitment, the action of adapter 
proteins, conformational changes and phosphorylation (109).  Once activated, Ras binds Raf 
kinase with high affinity recruiting inactive Raf to the membrane.  Raf binds to Ras-GTP 
through both a Ras binding domain (RBD) and a cysteine-rich domain (CRD) (97).  If S-259 
on Raf is phosphorylated, the adapter protein 14-3-3 can bind to that phosphoserine residue 
and inhibit successful Raf dimerization with Ras (109).  The binding to Ras induces a 
conformational change in Raf, exposing conserved sites S-338 and Y-341 for 
phosphorylation by various kinases (97, 162).  Following recruitment to the cell membrane, 
proper conformational changes and phosphorylation, Raf is eventually activated.    
 
The principal downstream target of Raf is the dual specificity kinase MEK, also known as 
MAPK kinase.  Within the catalytic domain of MEK lies two serine sites that require 
phosphorylation by Raf to become functional: S-217 and S-221 (4).  The inactivation of 
MEK, and the obstruction of the proliferative signal, requires the dephosphorylation of both 
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conserved serine residues (4, 27).  MEK is responsible for the phosphorylation and activation 
of the serine/threonine kinase Erk.  Erk is highly regulated and requires both tyrosine and 
threonine phosphorylation to be operative, specifically at sites Y-185 and T-183 (120, 173).  
Additionally, if either of theses sites becomes dephosporylated, Erk loses all of its catalytic 
activity (173).  Following activation by MEK, Erk dimerizes and regulates several 
intracellular targets, notably certain transcription factors (121). 
 
One target of activated Erk is the AP-1 (activating protein-1) family of transcription factors, 
which includes c-jun and c-fos.  Erk regulates these proteins by serine phosphorylation, after 
which they form the homodimers or heterodimers necessary for DNA binding (20, 62, 107).  
Additionally, Erk activates Elk-1, another transcription factor that upregulates the expression 
of important signaling proteins such as c-fos (51).  It has been proposed that in addition to its 
role in differentiation and cell cycle progression, c-fos also induces the expression of c-myc, 
(105).  However, the expression and activation of c-myc appears to be regulated by two 
pathways, one that is dependent and one that is independent of c-fos (23, 105). 
 
Following the formation of Ras-GTP, a signaling cascade ensues resulting in the activation of 
scores of transcription factors (81).  These transcription factors have the capability of 
activating and negatively regulating the expression levels of each other and themselves, 
helping to maintain a proper balance.  These proteins have the power to control functions that 
are essential to T cell expansion, including IL-2 secretion, proliferation, survival and cell 
cycle progression (104, 126, 138). 
 
Negative regulation of the Ras/Erk pathway 
 
In order to prevent uncontrolled cell growth and differentiation due to Ras signaling, several 
negative regulatory mechanisms are in place.  First and possibly most important is the 
involvement of Ras-GAP, which stimulates the GTPase activity of Ras.  Ras-GAP directly 
binds to Ras, leading to the hydrolysis of GTP to GDP and the inactivation of Ras (146, 148, 
157) (Figure 2.3).  The phosphatase SHIP also plays an important role in the control of Ras 
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signaling.  It has been revealed that SHIP can bind directly to Shc following IL-2 stimulation, 
displacing the Grb2/Sos dimer (30, 98).  Within the Ras/Erk pathway, there is also a negative 
feedback loop that controls signal output.  Active Erk can phosphorylate Sos, causing it to 
dissociate from Grb2 (84). Lastly, there are several non-specific, cytosolic protein 
phosphatases that dephosphorylate the proteins involved in the Ras/Erk cascade.  Together, 
all of these mechanisms help control the cellular functions induced by Ras.    
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2.1.4  Signal crosstalk 
 
No signaling pathway is able to elicit a full cellular response on its own.  Distinct pathways 
often converge on select signaling molecules, which require multiple inputs for full 
activation and functionality.  For example, both the PI3K and Ras/Erk pathways are needed 
to fully activate the anti-apoptotic protein Bad and the transcription factor c-myc (63, 127).  
This convergence is also seen at the level of the response brought on by these pathways.  For 
example, full proliferation following IL-2 stimulation requires the activation of at least two 
of the three major signaling pathways discussed (43, 110). 
 
Additionally, the signaling proteins in one pathway have the potential to laterally modulate 
proteins in other pathways, altering the dynamics and balance of the signal transduction 
network (Figure 2.4).  One striking instance of crosstalk in the IL-2 signal network is the 
direct activation of PI3K by Ras-GTP (68, 76).  The p110 subunit of PI3K can be directly 
bound and stimulated by Ras-GTP, and thus activating PI3K (130, 141).  The adapter protein 
Shc can also activate both Ras and PI3K simultaneously, with the aid of adapter proteins 
Grb2 and Gab2 (58, 60, 115).  The co-localization of these pathways is the perfect 
opportunity for Ras to bind p110 and positively modulate the PI3K pathway.  
 
Utilizing PI3K inhibitors, it has been shown that both MEK and Erk are partially dependent 
on PI3K induction (28, 38, 164).  One theory is that PI3K influences Ras through the PH 
domain-containing adapter protein Gab2. Following IL-2 stimulation, PI3K generates PIP3 in 
the plasma membrane, which recruits Gab2 through its PH domain (48, 129).  Grb2/Sos 
associates with the membrane bound Gab2 with surprisingly high affinity, allowing for 
Sos/Ras interaction to occur away from the IL-2 receptor complex (47, 172).  This secondary 
mechanism is thought to increase signal transmission through the Ras/Erk pathway.   
 
An additional instance of crosstalk between signaling pathways is the serine phosphorylation 
of STAT dimers by Erk.  After tyrosine phosphorylation by Jaks, STAT molecules dimerize 
and translocate to the nucleus.  During this process, or once within the nucleus, dimerized 
STATs are subject to dephosphorylation, causing them to disassemble and become inactive.  
Erk phosphorylation of STAT dimers can stabilize their association and help protect against 
dephosphorylation from cytosolic or nuclear phosphatases (46, 65, 122).   
 
The crosstalk that occurs between signaling pathways does not always enhance signaling; it 
can also serve a regulatory function.  One well known example of this is the inhibition of Raf 
through Akt-mediated phosphorylation.  Active Akt can phosphorylated Raf on S-259, which 
permits adapter protein 14-3-3 binding to Raf, hindering its ability to associate with Ras and 
become activated (133, 176).  The implication of this mechanism is that PI3K signaling can 
have conflicting positive and negative effects on Ras/Erk pathway activation.  With multiple 
pathways that can potentially both positively and negatively modulate each other, an 
alteration in the balance of the signaling network, due to crosstalk, may be a realistic 
explanation behind the IL-2/IL-4-induced synergistic growth response. 
 
Figure 2.4  Crosstalk in the IL-2/IL-4 system  There are several possible crosstalk 
pathways occurring the IL-2/IL-4 co-stimulation system.  Erk has the potential to serine 
phosphorylate the STAT dimers, increasing their stability.  Ras is also able to positively 
modulate the activation of PI3K by phosphorylating the catalytic domain.  Following the 
creating of PIP3 at the membrane by PI3K, Gab2 will bind to it and recruit Grb2/Sos, which 
in turn can activate Ras away from the receptor complex.  It has been demonstrated that Akt 
will phosphorylate Raf, preventing its association with Ras.  Additionally, Erk can 
phosphorylate and inhibit the exchange factor Sos, creating a negative feedback loop within 
the Ras cascade 
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CHAPTER 3 
 
CHARACTERIZATION OF SIGNALING PATHWAYS THAT GOVERN  
T CELL PROLIFERATION IN RESPONSE TO  
INTERLEUKIN-2 AND INTERLEUKIN-4 
 
3.1  INTRODUCTION 
 
Cells sense and respond to chemical and physical stimuli through signal transduction 
networks, which mediate cell proliferation, differentiation, migration, and survival (32).  
Interleukin-2 (IL-2) and interleukin-4 (IL-4) are key regulators of the adaptive immune 
response, controlling T cell expansion and differentiation (31, 36).  It has been reported that 
IL-2 and IL-4 co-stimulation induces T cell proliferation in a synergistic manner; at lower 
concentrations of IL-2 and IL-4, the collective proliferation rate is greater than the additive 
effects elicited by each cytokine alone (61, 71).  At the level of intracellular signaling 
networks, the basis for this synergy is unknown. 
 
Signaling events stimulated by IL-2 are mediated by its high affinity receptor complex, 
composed of the IL-2Rα, IL-2Rβ and γc subunits (39, 54).  IL-4 binds to a dimeric receptor, 
consisting of the IL-4Rα and γc (56).  Assembly of these high-affinity complexes is a multi-
step process, whereby the common γc subunit is recruited after the initial binding of the 
cytokine, a requirement for initiation of signaling (55, 65).  By the same token, γc recruitment 
stabilizes cytokine/receptor association.  Thus, to the extent that IL-2 and IL-4 receptors 
compete for a limited pool of γc, the two cytokines are expected to antagonize one another.  
Such antagonism has been observed, but it is apparently uni-directional; IL-4 causes partial 
inhibition of IL-2 binding, whereas IL-4 binding is unaffected by the presence of IL-2 (11, 
18). 
 
As described in Chapter 2, IL-2 and IL-4 receptors activate both common and unique 
signaling pathways.  IL-2 receptors activate the Ras/extracellular signal-regulated kinase 
(Erk), phosphoinositide 3-kinase (PI3K)/Akt and Janus kinase (Jak)/STAT5 pathways (6, 
 57
20).  IL-4 is unique among cytokines in that it does not induce Ras/Erk; it does, however, 
activate the PI3K/Akt pathway as well as a distinct Jak/STAT6 cascade (30, 56, 75). 
 
Following IL-2 or IL-4 addition, the kinases Jak1 and Jak3 are recruited and bind to the 
receptor complexes, where they phosphorylate specific, conserved tyrosine residues on the 
IL-2Rβ or the IL-4Rα (34, 37).  STAT5 and STAT6 are the primary downstream proteins 
targeted for phosphorylation by Jak1 following their association with the IL-2β and the IL-
4Rα, respectively (35, 51, 76).  Phosphorylation of these transcription factors results in 
reciprocal dimerization of the STATS, translocation of STAT dimers to the nucleus, and 
DNA binding (14, 33). 
 
The lipid and serine/threonine kinase PI3K, comprised of a p85 regulatory domain and a 
p110 catalytic domain, is activated following treatment with either IL-2 or IL-4 and is 
responsible for cell proliferation and survival (19, 77).  After cytokine stimulation, PI3K is 
recruited to and associates with the receptor after which the necessary conformational 
changes occur for activation (26, 53).  Active PI3K produces 3’ phosphoinositide (PI) lipids 
[PI(3,4,5)P3 and PI(3,4)P2] that act as second messengers, recruiting downstream signaling 
proteins to the plasma membrane (48, 72).  One 3’ PI-dependent target is the serine/threonine 
kinase Akt, which mediates numerous pro-survival and cell cycle progression pathways (1, 7, 
10). 
 
The Ras/Erk cascade is a well characterized signaling pathway stimulated by most growth 
factors and cytokines to control cell proliferation and differentiation (25, 49).  
Phosphorylation of the IL-2R complex provides a binding site for, and promotes the 
assembly of, the Shc/Grb2/Sos complex, which controls activation of Ras at the plasma 
membrane (50, 58).  Ras then triggers a signaling cascade of protein kinases that include Raf, 
MEK, and Erk, which are regulated by phosphorylation (4, 40, 59).  Once active, Erk 
translocates to the nucleus where it phosphorylates transcription factors such as c-fos, c-jun, 
Elk-1 and c-myc (12, 23, 60). 
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Although many studies have contributed to the knowledge of the roles of signaling proteins 
in T cell growth, little has been done in the analysis of these proteins following co-
stimulation with IL-2 and IL-4.  We have sought to characterize signal transduction pathways 
activated by IL-2 and IL-4 receptors in the HT-2 cell line, a helper 2 (TH2) T cell line derived 
from mouse.  This cell line is an ideal model because it constitutively expresses IL-2 and IL-
4 receptors, does not normally make its own IL-2 or IL-4, and proliferates in response to IL-2 
(29, 43).  We show that IL-2-stimulated HT-2 cell proliferation in static culture is affected by 
IL-4 in two distinct ways.  IL-4 antagonizes proliferation at early times, effectively 
prolonging the lag phase, yet on the other hand it delays the onset of stationary phase and 
allows a higher cell density to be achieved.   
 
In conjunction with these growth studies, activation levels of key signaling proteins were 
measured following IL-2 and IL-4 addition – specifically Akt, Erk, STAT5 and STAT6.  At 
low but not high concentrations of IL-2, IL-4 partially inhibits IL-2 induced activation of 
Akt, Erk and STAT5, consistent with the aforementioned antagonism of IL-2 binding and 
saturation of the intracellular signaling machinery.  This effect cannot completely explain the 
inhibition of IL-2-stimulated proliferation, however, because the IL-4-induced extension of 
lag phase is observed at higher concentrations of IL-2.  IL-2-stimulated activation of Akt, 
Erk, and STAT5 was found to be transient, subject to depletion of IL-2 from the medium, 
and IL-4 does not extend the duration of those signals.  By comparison, IL-4-stimulated 
activation of STAT6 is sustained, and we speculate that this unique pathway is responsible 
for most if not all of the effects of IL-4 in these cells. 
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3.2  MATERIALS AND METHODS 
 
Cell culture and reagents 
Human recombinant IL-2 and murine recombinant IL-4 were acquired from Peprotech.  
Other cell culture reagents were purchased from Invitrogen.  The murine T helper cell line 
HT-2 was obtained from American Type Culture Collection.  The culture medium consisted 
of Advanced RPMI 1640 base supplemented with 2% fetal bovine serum, 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 50 μM β-mercaptoethanol and 10 
U/ml of recombinant human IL-2 (47, 74).  The cells were subcultured in 75 cm2 T flasks in 
an incubator at 37 ºC and 5% CO2.   
 
Antibodies against phospho-specific Akt (pSer 473), phospho-specific p44/p42 MAPK (pThr 
202/pTyr 204), phospho-specific STAT5 (pTyr 694), total STAT5, phospho-specific STAT6 
(pTyr 641) and total STAT6 were from Cell Signaling Technology.  Antibodies against total 
Akt 1/2 and total Erk-1 were from Santa Cruz Biotechnology.  Anti-rabbit and anti-goat 
secondary antibodies were acquired from Cell Signaling Technology and Sigma, 
respectively.  The pharmacological inhibitors U0126, PD98059, LY303511 and LY294002 
were purchased from Calbiochem.  Dimethyl sulfoxide (DMSO) was purchased from Fisher 
Scientific. 
 
Growth curve analysis 
HT-2 proliferation analyses were performed in non-treated, 47 mm plates.  Briefly, cells were 
seeded at 3x104 cells/mL, in a total volume of 3 mL, with medium containing the indicated 
cytokine concentrations.  Approximately every 12 hours, sampling was performed by 
scraping, mixing and counting the number of cells within each plate using a Z1 Coulter-
Particle Counter (Beckman Coulter). 
 
Preparation of detergent lysates 
For short-term stimulation experiments, HT-2 cells were incubated in cytokine-free media for 
4 hours prior to cytokine addition to allow for signaling to return to a basal level.  Cells were 
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counted using a Z1 Coulter-Particle Counter and inoculated at a density of 2.5x105 cells/mL.  
For each lysate, 12 mL of cell culture was removed and treated with appropriate cytokines; at 
the pre-determined time, the cells were pelleted and resuspended in 200 μL of lysis buffer 
(50 mM HEPES pH 7.11, 100 mM NaCl, 1% Triton X-100, 50 mM β-glycerophosphate pH 
7.3, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 5 mM sodium fluoride, 1 
mM EGTA and 10 μg/mL each of aprotinin, leupeptin, pepstatin A and chymostatin) (28).  
All chemicals were obtained from either Fisher Scientific or Sigma.  Cells were vortexed and 
incubated on ice for 20 minutes, then centrifuged at 6000xg at 4 ºC for 15 minutes to remove 
cellular debris.  The supernatants were collected and transferred to a fresh tube, and the 
lysates were stored at –20 ºC. 
 
For long-term stimulation, 30 mL of cells were incubated in a 15 cm non-treated petri dish at 
an initial density of 3x104 cells/mL with media containing the indicated cytokine 
concentrations.  Prior to lysis, each plates was scraped with a cell lifter to remove any 
adherent cells from the surface; the cells were mixed and counted to determine cell density.  
Next, 25 mL of cells were pooled and lysed by the method described above. 
 
Adhesion studies 
In non-treated, 10 cm petri dishes, 10 mL of cells were incubated at a density of 3x104 
cells/mL for IL-2/IL-4 combined treatment and at a density of 1x105 cells/mL for IL-4 only 
stimulation.  The higher initial cell density for the IL-4-only scenario compensates for the 
lack of cellular proliferation in the absence of IL-2.  At each time point, the numbers of cells 
in both the supernatant and attached to the plate were assessed using the Z1 Coulter-Particle 
Counter. 
 
Experiments were also performed to determine if, upon removal of IL-4, the adhered cells 
would detach.  The above experimental setup was repeated, and the cells were given four 
days to fully adhere.  The medium was removed and replaced with medium containing IL-2 
only, and an initial cell density on the plate was determined.  Over several days, the numbers 
of cells in the supernatant and adhered to the plate were measured as described above. 
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Quantitative Western blotting 
Pooled cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE).  Samples were boiled for five minutes after addition of 4X 
Laemmli reducing sample buffer (Boston Bioproducts), loaded and separated in 10% 
acrylamide gels, and transferred to PVDF membranes (44, 69).  Membranes were blotted for 
proteins using the indicated primary antibodies and imaged using horseradish peroxidase-
conjugated secondary antibodies and Super Signal West Femto Maximum Sensitivity 
Substrate (Pierce). The blots were imaged and quantified using a Bio-Rad Fluor-S 
MultiImager.  Signaling protein activation was determined by normalizing the amount of 
phosphorylated protein by the total amount of that protein, quantified in parallel. 
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3.3  RESULTS 
 
The main objective of this work was to characterize the responses of HT-2 cells to IL-2, IL-4 
and IL-2/IL-4 co-stimulation, both in terms of cell responses such as proliferation and at the 
level of intracellular signal transduction pathways.  Four major signaling pathways have been 
implicated in the IL-2-/IL-4-receptor network, and one end-point protein was selected to 
represent the activity of each: Akt, Erk, STAT5 and STAT6.  We hoped to correlate 
inducible changes in signaling behavior to any observed alterations in HT-2 growth patterns 
following IL-2/IL-4 co-stimulation. 
 
3.3.1  Characterization of HT-2 cell proliferation and intracellular signaling stimulated 
by IL-2: effect of IL-2 dose. 
The kinetics of HT-2 cell proliferation, measured as a function of time in static culture, were 
evaluated for various initial concentrations of IL-2 (Figure 3.1 A).  Not surprisingly, these 
kinetics exhibit a lag phase in the first 12 hours or so.  Thereafter, the population density 
increases at a rate that depends on the initial concentration of IL-2, with saturation of the 
apparent rate at IL-2 concentrations of ~ 50 pM and above.  The lower range of IL-2 
concentrations, which represent plausible biological levels (21, 39), produce a definite 
growth response without saturating the high-affinity receptors.  At later times, a plateau in 
cell density is observed, and its onset is a function of IL-2 dose; concentrations significantly 
greater than 50 pM continue to yield gains in the duration of robust cell growth.  These 
kinetics are characteristic of the well-known mechanism by which receptor-mediated 
endocytosis mediates clearance of IL-2 and other ligands from the medium over time (68). 
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Figure 3.1  Growth and signaling dose response of T cells following cytokine stimulation  
A) HT-2 cells were incubated with varying IL-2 concentrations to characterize the 
proliferative response of the cell line.  The cell density was determined in triplicate 
(represented here as mean ± S.E.), and the data are representative of two independent 
experiments.  B) The activation profiles of key proteins were monitored by quantitative 
immunoblotting as a function of cytokine dose; the stimulation time was 1 hour.  In three 
independent experiments, IL-2-stimulated activation of Akt, Erk and STAT5 was measured 
in triplicate (mean ± S.E., n=3).  IL-4-stimulated STAT6 activation was measured in 
triplicate in two independent experiments (mean ± S.E., n=2).  In each experiment, the basal 
rate was subtracted, and the stimulated levels were normalized by the maximum value.  The 
normalized dose response, y, was fit to the Hill function: y = ymax*Cm/{EC50m + Cm), where C 
is the concentration of cytokine and ymax, EC50, and m are fit parameters.  The exponent m 
was constrained so that only values greater than or equal to 1 were allowed; m = 1 except 
where noted. 
 
Next, dose response curves were constructed for the activation of Akt, Erk and STAT5 
stimulated by IL-2 and of STAT6 stimulated by IL-4 (Figure 3.1 B).  Estimated values of the 
EC50, the concentration of cytokine that elicits half-maximal activation, were in the range of 
~ 2–3 pM for all responses.  Considering the reported KD values of IL-2 and IL-4 in the range 
of 10–50 pM, the results suggest that receptor-mediated signaling through these pathways is 
subject to saturation, perhaps at the level of a common signaling component.  This would be 
consistent with recruitment of a limiting pool of Jak1 or Jak3, for example. 
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Based on the results thus far, it is clear that signal transduction readouts in HT-2 cells, 
measured at quasi-steady state after a relatively short period of stimulation, do not correlate 
quantitatively with IL-2-stimulated proliferation.  An IL-2 concentrations of ~ 15–20 pM is 
sufficient to saturate the initial signaling responses but not the rate of cell proliferation prior 
to the onset of stationary phase.  This observation is entirely consistent with the now classic 
conceptual model of IL-2 receptor signaling, which underscored the importance of the 
duration of signaling, and not only its peak magnitude, as a key determinant of T cell 
proliferation (45). 
 
3.3.2  IL-4 initially antagonizes IL-2-stimulated signaling and proliferation of HT-2 cells 
but also fosters higher maximal cell densities in static culture. 
At the level of stimulated DNA synthesis or cell proliferation, both synergistic and 
antagonistic effects of IL-2 and IL-4 co-stimulation have been reported (11, 61).  Analysis of 
the kinetics of HT-2 cell proliferation revealed aspects of both such effects under static 
culture conditions, in an IL-4 dose-dependent manner (Figure 3.2 A&B).  IL-4 initially 
antagonizes IL-2-stimulated HT-2 cell proliferation, delaying the emergence of the culture 
from lag phase.  On the other hand, IL-4 also delays the onset of stationary phase, prolonging 
cell growth such that a higher cell density is achieved compared with IL-2 alone.  These 
qualitative features are observed at a concentration of IL-2 close to the EC50 for signal 
transduction (2 pM; Fig. 3.2 A) as well as at a significantly higher IL-2 dose (15 pM; Fig. 3.2 
B).  In the absence of cytokines, HT-2 cells do not proliferate and eventually undergo 
apoptosis.  Additionally, it was confirmed that IL-4 alone does not elicit significant HT-2 cell 
proliferation. 
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Figure 3.2  The response of HT-2 cells to IL-2/IL-4 co-stimulation  A-B) Growth kinetics 
of HT-2 cells were monitored following stimulation with IL-2 only, IL-4 only or 
combinations of IL-2 and IL-4.  The cell density was measured in triplicate (mean ± S.E.) 
and the displayed data are representative of three independent experiments.  A) −T − no 
cytokines, −T− 2 pM IL-4, − − 100 pM IL-4, −●− 2 pM IL-2, −●− 2 pM IL-2/2 pM IL-4, 
− − 2 pM IL-2/100 pM IL-4  B) −T − no cytokines, −T− 10 pM IL-4, − − 300 pM IL-4, 
−●− 15 pM IL-2, −●− 15 pM IL-2/10 pM IL-4, − − 15 pM IL-2/300 pM IL-4  C&D) In 
order to determine early signaling pathway activation in the presence of IL-2 and IL-4, 
experimental matrices were designed:  one with a sub-saturating dose of 2 pM IL-2 (mean ± 
S.E., n = 3) and the second with a saturating concentration of 15 pM IL-2 (mean ± S.E., n = 
4).  Cells were treated with the indicated doses of IL-2 and/or IL-4 for 1 hour, lysed and 
analyzed in triplicate.  E) HT-2 cells were treated with 2 pM IL-4, alone or in combination 
with 1 nM IL-2, for one hour.  Cell lysates were probed for STAT6 activation.  F) For the 
pre-treatment samples, HT-2 cells were stimulated with 1 nM IL-2 for 24 hours prior to the 1 
hour stimulation with 2 pM IL-4.  The other samples underwent concurrent stimulation of 1 
nM IL-2 and 2 pM IL-4 for 1 hour.  Active STAT6 levels are compared between the two 
circumstances. 
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In an effort to determine how IL-4 delays the onset of IL-2-stimulated HT-2 cell growth, 
various combinations of the two cytokines were administered, and Akt, Erk, and STAT5 
phosphorylation measurements were conducted after 1 hour of stimulation.  These 
measurements were designed to capture the initial signaling burst that is thought to be 
required for cell cycle progression (38).  At a sub-saturating dose of 2 pM IL-2, a high dose 
of IL-4 (100 pM) partially inhibits all of the IL-2-stimulated pathways measured (Figure 3.2 
C).  The degree of inhibition, ranging from approximately ~ 30–70%, is consistent which the 
reported antagonism of IL-2/IL-2R binding (5, 11).  Of the signaling readouts tested, the 
observation that Akt activation was subject to the greatest degree of inhibition is at least 
qualitatively consistent with the notion that IL-2 and IL-4 receptors compete not only for γc, 
Jak1, and Jak3, but presumably also for recruitment of PI3K and other components required 
for activation of Akt.  At a higher dose of 15 pM IL-2, at which IL-4 still effectively 
antagonizes IL-2 receptor binding (11), the antagonism of IL-2-stimulated Akt, Erk, and 
STAT5 signaling is significantly ameliorated (Figure 3.2 D).  This is not inconsistent with 
the postulated competition mechanism outlined above, because the signaling pathways are 
saturated at this IL-2 dose (Fig. 3.1 B); thus, a partial reduction in the number of activated 
IL-2 receptors is expected to have only a modest effect. 
 
Consistent with the inability of IL-2 to antagonize IL-4/IL-4R binding (52), it was confirmed 
that IL-4-stimulated STAT6 phosphorylation, assessed at a half-maximal concentration of 2 
pM IL-4, is unaffected by the presence of a saturating IL-2 dose (Figure 3.2 E).  An 
alternative possibility, based on the observation that chronic IL-2 stimulation of T cells 
results in significant downregulation of the γc subunit (67), is that IL-2 stimulation might 
indirectly affect IL-4 receptor signaling over time.  This possibility was ruled out, as 
pretreatment with 1 nM IL-2 for 24 hours had no effect on IL-4-stimulated STAT6 
phosphorylation (Figure 3.2 F).  Apparently, any γc subunit downregulation was not of a 
sufficient magnitude to impact IL-4 receptor signaling in our cells, and it is concluded that 
IL-4 stimulation of STAT6 activation is effectively independent of IL-2 receptor signaling. 
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Comparing these data, the initial inhibition of IL-2-stimulated HT-2 cell proliferation by IL-4 
cannot be entirely explained by the inhibition of Akt, Erk, and STAT5 signaling, because this 
effect on proliferation is apparent even at an IL-2 concentration (15 pM) that fosters maximal 
signaling in the presence of IL-4 (Fig. 3.2 B & D).  One possibility is that at least one 
signaling pathway required for IL-2-stimulated proliferation is not saturated at this dose and 
is therefore more strongly affected by antagonism of IL-2/IL-2R.  An alternative and perhaps 
more likely possibility is that a pathway unique to the IL-4 receptor, such as STAT6, 
antagonizes or otherwise stalls the sequence of molecular processes required for the onset of 
cell growth. 
 
3.3.3  IL-2/IL-4 co-stimulation of T cells yields transient activation of Akt, Erk and 
STAT5 coupled with sustained STAT6 signaling. 
 
Given the established importance of the duration of IL-2 receptor-mediated signaling in T 
cell proliferation (66), we sought to characterize the kinetics of IL-2-stimulated signaling and 
the influence of IL-4 on those kinetics (Figure 3.3).  At the same sub-saturating dose of 2 pM 
IL-2 used above, phosphorylation of Akt, Erk, STAT5 and STAT6 reached peak levels 
within ~ 30 minutes and decayed thereafter.  Within ~ 6 hours, IL-2-stimulated Erk and 
STAT5 phosphorylation had decayed to approximated basal levels, whereas Akt 
phosphorylation was somewhat more sustained (Fig. 3.3), consistent with its lower EC50 
concentration (Fig. 3.1 B).  The presence of 100 pM IL-4, mirroring the conditions used 
above (Fig. 3.2 A & C), resulted in the partial inhibition of peak signaling as expected; 
furthermore, the presence of IL-4 did not prolong the time course of IL-2-stimulated 
signaling (Fig. 3.3).  By comparison with IL-2 stimulated signaling, IL-4-stimulated STAT6 
phosphorylation was sustained throughout the time course. 
 
Figure 3.3  Signaling duration following treatment with 2 pM IL-2  HT-2 cells were 
dosed with either 2 pM IL-2 (−●−) or 2 pM IL-2 and 100 pM IL-4 (− −).  In two 
independent experiments, samples were collected over a 12 hour time course and analyzed in 
triplicate to determine the signaling kinetics of Akt, Erk, STAT5 and STAT6 (mean ± S.E., n 
= 2). 
 
Distinct mechanisms that might explain the transient nature of the IL-2-induced signals were 
considered.  The first is that low concentrations of IL-2 (e.g., 2 pM) might be depleted from 
the extracellular medium, as a consequence of receptor-mediated endocytosis or the action of 
cell-derived proteases.  This mechanism was deemed highly plausible based on our 
interpretation of the proliferation dose response presented in Fig. 3.1 A.  Another common 
consequence of receptor-mediated endocytosis is downregulation of receptors from the cell 
surface, but this mechanism is not expected when the ligand concentration is well below the 
effective KD of high-affinity receptor binding (46).  Another plausible mechanism is an 
adaptive response at the level of signal transduction, typically achieved through negative 
feedback in the system.  The ligand depletion mechanism was tested by re-feeding the cells 
with 2 pM IL-2 after the signaling levels have decayed to near basal levels (t = 6 hours); 
upon re-feeding, the IL-2-stimulated levels of phosphorylated Erk and STAT5 rebounded to 
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near peak levels (Figure 3.4 A), confirming that ligand depletion is at least a major 
contributor to, if not the root cause of, the decay in IL-2 receptor-mediated signaling. 
 
As a follow-up experiment, HT-2 proliferation was monitored after re-stimulation with 2 pM 
IL-2; if ligand depletion is significant as asserted above, one would expect IL-2 re-feeding to 
induce a second round of proliferation beyond the stationary phase otherwise observed.  
Indeed, this was found to be the case (Figure 3.4 B).  Together, these results indicate that 
transient IL-2 signaling in static culture is caused at least in part by a ligand depletion effect. 
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Figure 3.4  Transient IL-2 signaling and HT-2 growth recover following cytokine re-
feed  A) HT-2 cells were dosed with 2 pM IL-2, and samples were collected for analysis at 
30 minutes and 6 hours post-stimulation.  At 6 hours, the remaining cells were resuspended 
in fresh medium containing 2 pM IL-2 and lysed after 30 minutes.  All time points were 
collected in triplicate, and phosphorylation of Erk and STAT5 was quantified by 
immunoblotting.  The blots shown are representative of two independent experiments.  B) 
Two HT-2 cultures were each treated with 2 pM IL-2, and their cell densities were monitored 
as a function of time.  After reaching stationary phase, one culture was resuspended in fresh 
medium containing 2 pM IL-2, whereas the second culture was left undisturbed.  The 
proliferative response was measured in triplicate (reported here as mean ± S.E.), and the data 
shown here are representative of two independent experiments. 
 
Kinetic analysis of signaling readouts induced by a higher dose of IL-2 (15 pM), in the 
absence or presence of a high IL-4 concentration, yielded results that were consistent with 
those outlined above (Figure 3.5).  As expected, IL-2-stimulated phosphorylation levels of 
Akt, Erk, and STAT5 are more prolonged than for the lower IL-2 dose, yet the signaling 
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readouts still decay to near basal levels within ~ 48 hours.  Here, as in the case of 2 pM IL-2 
stimulation, the presence of IL-4 does not enhance the persistence of the IL-2-stimulated 
signals.  By comparison, in the presence of IL-4, STAT6 phosphorylation is sustained over 
the course of several days (Fig. 3.5).  At a lower, sub-saturating concentration of IL-4 (10 
pM), the magnitude of the response is lower yet similarly sustained, indicating that IL-4-
stimulated signaling, at least through STAT6, is not subject to the same ligand depletion 
effect affecting IL-2 receptor-mediated pathways. 
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Figure 3.5  Transient signaling in response to 15 pM IL-2  HT-2 cells were stimulated 
with either 15 pM IL-2 alone or in combination with 10 pM or 300 pM IL-4.  
Phosphorylation of Akt, Erk, STAT5 and STAT6 were measured by quantitative 
immunoblotting (mean ± S.E.). 
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3.3.4  IL-2-stimulated HT-2 cell proliferation is perturbed by pharmacological 
inhibitors of intracellular signaling pathways. 
To further elucidate the roles of the PI3K/Akt and the Ras/Erk signaling pathways in IL-2-
induced T cell proliferation, we assessed the sensitivity of HT-2 cell growth kinetics to 
pharmacological inhibition of PI3K and MEK, the kinases most proximal to Akt and Erk, 
respectively.  The inhibitors used are LY294002 in the case of PI3K (57, 73) and both 
PD098059 (3, 27) and U0126 (17, 62) in the case of MEK.  It was verified that proper 
concentrations of these pharmacological inhibitors block their intended targets in HT-2 cells 
(Figure 3.6 A); PI3K-dependent Akt phosphorylation induced by IL-2 is effectively blocked 
in the presence of 50 μM LY294002, and both 50 μM PD098059 and 10 μM U0126 are 
effective in preventing IL-2-stimulated Erk phosphorylation. 
 
Testing the effects of these inhibitors on HT-2 cell proliferation revealed differential 
sensitivity to the inhibitors of PI3K- and MEK-dependent signaling (Figure 3.6 B).  Whereas 
the PI3K inhibitor LY294002 completely abrogates IL-2-stimulated proliferation, inhibition 
of MEK/Erk has a significant but less severe effect by comparison. 
 
The dramatic effect of LY294002 on HT-2 cell growth is potentially problematic in light of 
recent studies showing that this compound is less selective than previously assumed (9, 13, 
15, 22).  A control compound, LY303511, which differs from LY294002 by an amine 
substitution of its morpholine oxygen group, does not inhibit PI3Ks (16), yet it inhibits 
several of the known unintended targets of LY294002, including mTOR, CK2, GSK3β, and 
MCP-1 (13, 22, 42).  Given these pharmacological profiles, comparison of IL-2-stimulated 
HT-2 cell proliferation in the presence of LY294002 or LY303511 suggests that inhibition of 
targets other than PI3K severely impacts HT-2 cell growth, but proliferation is blocked 
completely when PI3K is inhibited (Figure 3.6 C). 
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Figure 3.6  Pharmacological inhibitors and their effect on HT-2 signaling and growth  
A) HT-2 cells were pre-treated with the indicated pharmacological inhibitor, as described in 
the main text, or DMSO as a vehicle only control.  Following stimulation with IL-2, cells 
were lysed and target signaling activation was determined in triplicate.  Representative blots 
are shown demonstrating the intended effects of the inhibitors.  B) HT-2 cells were pre-
treated with DMSO, LY294002 or PD098059 prior to addition of 15 pM IL-2 and the 
resulting growth was observed.  The cell density was measured in triplicate (represented here 
as mean ± S.E.), and the data are representative of two independent experiments.  C) HT-2 
cells were pre-treated with either LY294002 or LY303511 then stimulated with 15 pM IL-2.  
The proliferative response was determined and compared for these inhibitors against a 
DMSO control.  Cell growth was monitored in triplicate (reported here as mean ± S.E.), and 
the data shown are representative of two independent experiments. 
 
Other experiments were performed to assess the effect of the timing of signaling pathway 
inhibition (Figure 3.7).  Administering inhibitors after 24 hours of 15 pM IL-2 stimulation 
(Fig. 3.7 A) did not prevent inhibition of IL-2-stimulated proliferation in these experiments, 
but the interpretation of these results is somewhat uncertain, as the kinetics presented in Fig. 
3.5 indicate that signaling levels are still elevated after 24 hours under these conditions. 
 
 72
Experiments were also performed to assess whether or not MEK/Erk inhibition would 
significantly impact IL-2-stimulated growth after the observed transient of Erk 
phosphorylation was completed (Fig. 3.7 B).  As expected, the results show that MEK 
inhibition has an increasingly diminished effect on HT-2 cell proliferation as the staggering 
of IL-2 and inhibitor addition becomes longer. 
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Figure 3.7  Growth analysis following inhibitor treatment at various times  A) Cells 
were stimulated with 15 pM IL-2 at the beginning of the growth studies.  After 24 hours, 
cells were treated with either 50 μM LY294002, 50 μM PD098059 or 10 μM U0126 and the 
resulting growth was monitored in triplicate (mean ± S.E.).  B) 10 μM of U0126 was added 
to HT-2 cells stimulated with 15 pM IL-2 at either 0, 24 or 48 hours.  The ensuing growth 
patterns were recorded in triplicate (reported here as mean ± S.E.) and compared to cells 
treated with DMSO only. 
 
3.3.5  IL-4 stimulates adhesion of HT-2 cells in static culture. 
 
IL-4 induces many significant changes in T cells, one of which is the expression of several 
surface receptor molecules, which mediate T cell adhesion and migration (8, 41, 70).  We 
observed that following treatment with IL-4 HT-2 cells, which normally are in suspension, 
began adhering to non-treated petri dishes (Figure 3.8 A-B).  In addition to this effect, the 
cellular phenotype was altered when exposed to IL-4:  cells became significantly larger while 
some started producing cellular extensions (Figure 3.8 C-D).   
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Figure 3.8  IL-4 provokes HT-2 cells to adhere and undergo phenotypic alterations  A) 
Following treatment of HT-2 cells with IL-2, the plate was washed and imaged (10x), 
displaying no cellular adhesion.  B) Even after washing, cells undergoing concurrent IL-2 
and IL-4 stimulation remain strongly attached to the plate surface (10x).  C) When cultured 
with IL-2, HT-2 cells are small, round and in suspension (20x).  D) After IL-4 exposure, the 
cell phenotype is altered, becoming larger, producing cellular extensions and adhering (20x). 
 
Next, the extent of HT-2 adhesion was assessed following co-stimulation with IL-2 and IL-4.  
It was found that the number of HT-2 cells attaching to a non-treated, polystyrene plate 
increased in an IL-4 dose-dependent fashion with time (Figure 3.9 A).  The addition of 1 pM 
IL-4 showed a negligible effect, whereas 100 pM and 300 pM IL-4 induced a dramatic 
adhesion response after 3 days in culture.  To verify that this observed phenomenon was 
induced by IL-4, experiments were performed in which cellular adhesion was quantified in 
the presence of IL-4 only (Figure 3.9 B).  The observed trends following exposure to 10 pM 
and 100 pM IL-4 were remarkably similar to the parallel experiments containing IL-2, 
suggesting that HT-2 adhesion is solely dependent upon IL-4.  
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Figure 3.9  Quantification of IL-4-induced adhesion  A) Following IL-2 and IL-4 addition 
the number of cells that adhered to a 10 cm non-treated petri dish was monitored over time in 
triplicate (mean ± S.E.).  B) Cells were treated with IL-4 only and resulting cellular adhesion 
was analyzed in triplicate (mean ± S.E.). 
 
To further investigate this adhesive response, we tested to see if continuous IL-4 stimulation 
was required to maintain HT-2 cell adhesion (Figure 3.10).  Cells were pretreated under the 
same IL-2/IL-4 co-stimulatory conditions used in the above adhesion studies, allowing 
adequate time for cell attachment to occur.  The IL-4-supplemented media was then removed 
and replaced with fresh media containing only IL-2.  The number of attached cells was 
monitored over several days; after approximately 4 days over half of the adhered cells had 
detached from the plates.  This behavior was consistent in all the conditions that induced 
significant adhesion (IL-2 plus 10 pM, 100 pM or 300 pM IL-4).  These results demonstrate 
that the IL-4-dependent HT-2 cell adhesion response is at least partially reversible.  
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Figure 3.10  Plated HT-2 cells begin to detach following IL-4 removal  Cells were 
allowed to adhere for 4 days in the presence of the cytokines indicated, after which they were 
incubated with 15 pM IL-2 only and the extent of cellular adhesion was quantified over time 
(adhered cells measured in triplicate and shown as mean ± S.E.). 
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3.4  DISCUSSION 
 
In this study, we assessed the functional responses and signal transduction stimulated by IL-2 
in T cells, administered alone or in combination with IL-4.  The mouse T cell line, HT-2, 
responded to both IL-2 and IL-4 as predicted, but the complexity of the response was 
somewhat surprising.  IL-4 initially delays and then later enhances the rate of IL-2 stimulated 
HT-2 proliferation.  Accordingly, IL-4 inhibits IL-2 stimulation of certain transient signaling 
intermediates while inducing sustained activation of IL-4-dependent proteins.  Although 
great headway was made, additional work will need to be performed to fully elucidate the 
mechanisms involved in the cellular response to concurrent IL-2 and IL-4 stimulation. 
 
Potential role and mechanism of adhesion 
Our work demonstrated that HT-2 cells undergo a strong adhesive response when stimulated 
with IL-4.  It is well documented that IL-4 induces expression of several surface molecules 
on T cells, resulting in cellular adhesion (8, 41, 70).  It will be beneficial to uncover which 
surface molecule is being induced by IL-4 in our cells and what signaling pathways are 
contributing to this response; STAT6-mediated transcription is a plausible mechanism for 
example.  Another interesting study might be to determine what adhesive is present in the 
medium or is being secreted by the HT-2 cells.  A likely candidate would be an 
exopolysaccharide that is recognized by IL-4-induced cell surface molecules (64).   
 
Along the same line of thought, it would be advantageous to establish the role that cell 
adhesion plays in IL-4 induced proliferation.  We surmise that IL-4-stimulated adhesion is a 
critical step that T cells must undergo before synergy can occur.  It would be interesting to 
see if the synergistic growth response to IL-2/IL-4 co-stimulation would still occur if HT-2 
adhesion was blocked, possibly through the utilization of non-adhesive plate coatings.  The 
next logical question that follows is whether STAT6 is responsible for this behavior in HT-2 
cells.  After blocking its effects, possibly through a siRNA approach (63), it could be easily 
determined if STAT6 is required for IL-4-dependent cell adhesion. 
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Crucial signaling contributions to IL-2-dependent T cell growth 
The results obtained from the pharmacological inhibitor experiments help to further elucidate 
the role of signaling in IL-2-stimulated growth of T cells.  These studies revealed a 
dependency on both the PI3K/Akt and the Ras/Erk pathways for optimal HT-2 cell 
proliferation in the presence of IL-2.  Separating the PI3K contributions from LY294002 
experimentation can be complicated because recent studies have shown that the compound is 
less selective than previously assumed.  LY303511 is a control substance that does not 
inhibit PI3Ks, but does inhibit several of the known, unintended targets of LY294002 (13, 
22, 42).  Comparison of IL-2-stimulated HT-2 cell growth in the presence of LY294002 or 
LY303511 (Figure 3.6) demonstrates that inhibition of targets other than PI3K severely 
impacts HT-2 cell growth, while inhibiting PI3K completely blocks proliferation.  Inhibitor 
studies also verified the importance of early IL-2 signaling events in the HT-2 proliferative 
response.  As expected, we demonstrated that MEK inhibition, from U0126 treatment, has an 
increasingly diminished effect on HT-2 cell growth as the length of time between IL-2 and 
inhibitor addition was elongated. 
 
Sub-saturating signaling from the IL-2 receptor allows for a greater synergistic response in 
the presence of IL-4 
It has been reported that T cells will undergo a stronger synergistic growth response in the 
presence of IL-4 when stimulated with sub-saturating concentrations of IL-2 (11).  To 
ascertain if this held true for our cellular system, the 2 pM IL-2 growth experiments were 
performed concurrently with the 15 pM doses to allow for direct evaluation.  By comparing 
the differences in final cell densities, it was shown that lowering the IL-2 concentration to a 
half-maximal value increased the IL-4-driven synergistic effect.  For 2 pM IL-2, addition of 
IL-4 caused an approximate increase in cell growth of 56%, whereas this increase was 
reduced to 31% for 15 pM IL-2 (Table 3.1).  Further confirmation of this phenomenon was 
discovered when no IL-4-dependent synergy was observed following HT-2 growth in the 
presence of 1 nM IL-2 (data not shown). 
Table 3.1  Synergy comparison between 2 pM and 15 pM IL-2 (mean ± S.E.) 
IL-2 only IL-2 + high dose IL-4 IL-2 only IL-2 + high dose IL-4
Trial 1 Cell Density 6.50E+04 1.10E+05 1.40E+05 1.75E+05
% Increase
Trial 2 Cell Density 1.00E+05 1.42E+05 2.20E+05 3.00E+05
% Increase
2 pM IL-2 15 pM IL-2
Average % Increase 56% ± 13% 31% ± 5%
69% 25%
42% 36%
 
 
IL-4 antagonism of IL-2-stimulated signaling is consistent with a competition mechanism 
It has been supposed that the antagonistic effect of IL-4 on IL-2-stimulated growth, when 
observed, is caused by competition for limiting amounts of the γc receptor subunit.  This 
assumption also appears to extend to the signaling initiated by IL-2 and IL-4, which 
demonstrate EC50 values lower than expected (Figure 3.1B) suggesting that receptor is 
subject to saturation.  Indeed, this effect could be initiated by a limitation of γc subunits, but 
is also consistent with a competition over available Jak1 and/or Jak3:  all of which are 
required to initiate signaling from the IL-2 and IL-4 receptors. 
 
Following co-stimulation of a sub-saturating dose of IL-2 (2 pM) with IL-4, it was shown 
that IL-4 partially inhibits all the IL-2-stimulated pathways measured.  This inhibition, 
ranging from 30%-70%, is consistent with the reported antagonism of the IL-2/IL-2R in the 
presence of IL-4.  The short-term analysis of Akt activation showed the most pronounced 
decrease in activation following co-stimulation, even though both IL-2 and IL-4 activate the 
PI3K/Akt pathway.  These results indicates that in addition to competition for γc and 
Jak1/Jak3, it is probable that there is a limitation of PI3K or another compound required for 
Akt activation.  The results obtained from IL-2/IL-4 co-stimulation with 15 pM IL-2 (Figure 
3.2D), which saturates the IL-2 signaling response, are also consistent with this hypothesized 
competition effect.  In this situation, it was expected that the partial reduction of activated IL-
2 receptors, induced by the introduction of IL-4, would have only a modest effect on the IL-
2-dependent signaling. 
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The impact of IL-2 on IL-4-dependent STAT6 activation was also scrutinized.  This work 
presented evidence that IL-4 is able to out-compete IL-2 for the limiting γc subunit.  
Theoretically, cells pretreated with IL-2 should occupy most of the available γc receptors 
prior to the addition of IL-4.  Since IL-2-pre-treatment studies indicated no negative effect on 
STAT6 activation (Figure 3.2F), it would imply that IL-4 is able to displace the pre-bound 
ligand and introduce competition between the IL-2 and IL-4 receptors.  Additionally, 
research performed in this study has verified that IL-4 stimulation of STAT6 is effectively 
independent of IL-2 receptor signaling. 
 
The initial antagonism of HT-2 growth by IL-4 cannot be fully explained by the 
corresponding inhibition of Akt, Erk and STAT5.  In the presence of a saturating dose of IL-
2 (15 pM) significant growth inhibition is observed accompanied by only a modest 
downregulation of IL-2-dependent signaling.  It is possible that another signaling pathway 
required for IL-2-dependent growth is not saturated following stimulation with 15 pM IL-2 
and is severely antagonized in the presence of IL-4.  Alternatively, a pathway unique to the 
IL-4 receptor, most probably STAT6, may be able to negatively regulate IL-2-driven HT-2 
proliferation. 
 
IL-2 signaling transience is brought on by ligand depletion 
We sought to characterize the kinetics of target signaling proteins following stimulation with 
2 pM IL-2.  Studies showed that IL-2-dependent signaling was transient by nature, whereas 
IL-4 signaling was sustained.  The activation levels of Akt, Erk and STAT5 peaked at 30 
minutes post cytokine addition followed by a steady decline in signaling intensity. Erk and 
STAT5 signals were returned to basal levels within 6 hours, whereas the Akt response was 
somewhat more sustained.  The IL-2 signaling kinetics in the presence of IL-4 mirrored IL-2 
and were accompanied by the expected inhibition of Akt, Erk and STAT5.  Interestingly, IL-
4 neither prolonged nor shortened the duration of IL-2-dependent signaling. 
 
One mechanism that might explain the IL-2 signaling transience is that that low 
concentrations of IL-2 might be depleted from the extracellular medium over time.  Receptor 
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bound ligand could be internalized though receptor-mediated endocytosis followed by 
degradation in intracellular lysosomes (2).  This mechanism of significant ligand depletion 
was deemed most plausible based on the IL-2 dose dependent growth profiles of HT-2 cells 
(Figure 3.1A).  The IL-2 re-feed experiments (Figure 3.4) verified that the IL-2 transient 
signaling is at least partially explained by significant ligand depletion.  This supposition was 
further proven by the kinetics analysis following HT-2 treatment with 15 pM IL-2, which 
demonstrated transient signaling of Akt, Erk and STAT5 lasting approximately 48 hours.  
The prolonged duration of IL-2 signaling is directly proportional to the increase in initial IL-
2 concentration, when compared against the 2 pM IL-2 kinetics.  Assuming a constant rate of 
receptor-mediated endocytosis and ligand degradation, these results are consistent with IL-2 
depletion as the root of signaling transience. 
 
Synergistic growth and the possible role of STAT6 
Studies have revealed the existence of a synergistic effect on T cell growth following co-
stimulation with IL-2 and IL-4.  The activation of Akt, Erk and STAT5 were shown to be 
transient and therefore have no direct link to the synergy growth phase.  In contrast, STAT6 
activation remained high throughout the time course in an IL-4 dose-dependent manner 
(Figure 3.5).  These results suggest that IL-4 signaling, at least through STAT6, is not 
plagued by the same ligand depletion that occurs in the IL-2 receptor system.  It is therefore 
tempting to speculate that STAT6 plays a central role in the induction of IL-2/IL-4 growth 
synergy.  This supposition is consistent with the action of STAT6 in inducing other 
transcription factors and IL-4 secretion, potentially establishing an autocrine STAT6 
activation loop.   
 
Although STAT6 activation is, in all probability, not the only necessary trigger for synergy, 
it can serve as a foundation for future work.  Other signaling proteins that could be targeted 
include transcription factors downstream of STAT6, such as GATA-3, NFAT and NFκB 
(24).  One study that would shed more light on the role of STAT6 in T cell growth is to 
knock down its expression through a siRNA approach (63).  After removing its effects and 
repeating the growth analysis, it could be determined if STAT6 is required for IL-4R-
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mediated inhibition or enhancement of IL-2-stimulated growth at early and later times, 
respectively.  
 
The completion of this work has great potential in augmenting the understanding of how T 
cell clonal expansion occurs following co-stimulation with IL-2 and IL-4.  This knowledge 
could be of vast importance in the research to ward off cancer and infectious diseases.  If 
continued, this work could easily be expanded to encompass other cell lineages and cytokines 
to help further understand and bolster the immune response. 
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